<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ther Adv Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ther Adv Psychopharmacol</journal-id>
<journal-id journal-id-type="publisher-id">TPP</journal-id>
<journal-id journal-id-type="hwp">sptpp</journal-id>
<journal-title-group>
<journal-title>Therapeutic Advances in Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2045-1253</issn>
<issn pub-type="epub">2045-1261</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31258889</article-id>
<article-id pub-id-type="pmc">6591664</article-id>
<article-id pub-id-type="doi">10.1177/2045125319858901</article-id>
<article-id pub-id-type="publisher-id">10.1177_2045125319858901</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The emerging role of omega-3 fatty acids as a therapeutic option in
neuropsychiatric disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-6286-554X</contrib-id>
<name>
<surname>Reimers</surname>
<given-names>Arne</given-names>
</name>
<xref ref-type="corresp" rid="corresp1-2045125319858901"></xref>
<aff id="aff1-2045125319858901">Department of Clinical Chemistry and
Pharmacology, Division of Laboratory Medicine, Klinikgatan 17, Lund, 22185,
Sweden</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ljung</surname>
<given-names>Hanna</given-names>
</name>
<aff id="aff2-2045125319858901">Department of Neurology and Rehabilitation
Medicine, Skåne University Hospital, Lund, Sweden</aff>
<aff id="aff3-2045125319858901">Department of Clinical Neurosciences Lund,
Faculty of Medicine, Lund University, Lund, Sweden</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2045125319858901">
<email>arne.reimers@med.lu.se</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>9</volume>
<elocation-id>2045125319858901</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2019</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The prevalence of neurologic and psychiatric diseases has been increasing for
decades and, given the moderate therapeutic efficacy and safety profile of
existing pharmacological treatments, there is an urgent need for new therapeutic
approaches. Nutrition has recently been recognized as an important factor for
the prevention and treatment of neuropsychiatric disorders. The omega-3
polyunsaturated fatty acids (n-3 PUFAs) eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) play critical roles in neuronal cell function and
neurotransmission as well as inflammatory and immune reactions that are involved
in neuropsychiatric disease states. A large number of experimental and
epidemiological studies provide a strong basis for interventional clinical
trials that assessed the clinical efficacy of n-3 PUFAs in various neurological
and psychiatric disorders. Most of these trials found beneficial effects of
dietary supplementation with EPA and DHA, and no serious safety concerns have
emerged. This review gives an introduction to recent findings on the clinical
efficacy of n-3 PUFAs in various neuropsychiatric disorders and the underlying
biochemical mechanisms. In addition, the reader will be enabled to identify
common methodological weaknesses of clinical studies on n-3 PUFAs, and
suggestions for the design of future studies are given.</p>
</abstract>
<kwd-group>
<kwd>EPA</kwd>
<kwd>DHA</kwd>
<kwd>n-3 PUFAs</kwd>
<kwd>neurologic disorders</kwd>
<kwd>psychiatric disorders</kwd>
<kwd>neuropsychiatric disorders</kwd>
<kwd>clinical studies</kwd>
<kwd>n-6/n-3 ratio</kwd>
<kwd>n-3 index</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-2045125319858901" sec-type="intro">
<title>Introduction</title>
<p>Neurological and mental disorders continue to be on the rise. The Global Burden of
Disease Report 2017 states that from 2007 to 2017, the number of neurological
disability-adjusted life years (DALYs) increased by 20.5%, while mental health DALYs
increased by 13.5%.<sup><xref ref-type="bibr" rid="bibr1-2045125319858901">1</xref></sup> Countries with a high sociodemographic index (SDI) are significantly more
affected than countries with a low SDI, which suggests a causal role of the Western lifestyle.<sup><xref ref-type="bibr" rid="bibr1-2045125319858901">1</xref></sup> Diet, physical activity, and social structures are critical factors that have
been linked to increases in neuropsychiatric and other disorders that are usually
referred to as lifestyle diseases. Concerning diet, high intakes of fruit,
vegetables, fish, and whole grains have been recommended to reduce such
risk.<sup><xref ref-type="bibr" rid="bibr2-2045125319858901">2</xref><xref ref-type="bibr" rid="bibr3-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr4-2045125319858901">4</xref></sup> The role of nutrition for
preventing and treating neuropsychiatric disorders is increasingly being recognized,
and it has recently been stated that ‘<italic>nutrition and nutraceuticals should
now be considered as mainstream elements of psychiatric
practice</italic>’.<sup><xref ref-type="bibr" rid="bibr3-2045125319858901">3</xref><xref ref-type="bibr" rid="bibr4-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr5-2045125319858901">5</xref></sup></p>
<p>Research on omega-3 polyunsaturated fatty acids (n-3 PUFAs) has grown exponentially
since researchers from Denmark visited Greenland in 1970 to study why the
cardiovascular mortality among the Inuit population was considerably lower than in
the Western countries.<sup><xref ref-type="bibr" rid="bibr6-2045125319858901">6</xref></sup> The researchers related their findings to the diet of the Inuit, which
consisted mainly of fish and meat from seals, whales, sea birds, and fur-bearing
animals. These foods contain large amounts of n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr6-2045125319858901">6</xref></sup> In the following decades, the health effects of n-3 PUFAs were studied
extensively, covering almost all medical conditions, including neurological and
psychiatric disorders. Such studies found that more isolated arctic populations with
traditional lifestyles and diets have lower rates of depression, anxiety, and
suicidality than less isolated or non-arctic populations. These findings have been
associated with diet-related factors, that is, n-3 PUFA intake.<sup><xref ref-type="bibr" rid="bibr7-2045125319858901">7</xref></sup></p>
<p>Research has shown that the significance of n-3 PUFAs for neuropsychiatric disorders
is based on their crucial role in neuronal cell functioning. Lipid imbalance in
intracellular biochemical processes and neuronal cell membranes may lead to changes
in brain functioning that can cause or aggravate neuropsychiatric disorders.<sup><xref ref-type="bibr" rid="bibr8-2045125319858901">8</xref></sup> The aim of this paper is to give an introduction to the clinical effects of
n-3 PUFAs in various neuropsychiatric disorders and their underlying biochemical
mechanisms. In addition, the reader will be enabled to identify common
methodological weaknesses of clinical studies on n-3 PUFAs. For more in-depth
reviews on the role of n-3 PUFAs in specific diseases, the reader is referred to the
respective references.</p>
</sec>
<sec id="section2-2045125319858901">
<title>What are n-3 PUFAs and how do they work?</title>
<p>Omega-3 fatty acids (FAs) are a type of PUFA. Polyunsaturated means that their carbon
chain contains two or more double bonds. <italic>Omega</italic> (<italic>ω</italic>)
is the last letter in the Greek alphabet, and omega-3 denotes that the first of
these double bonds is located between the 3rd and the 4th carbon atom seen from the
last (the <italic>omega</italic>-) atom of the carbon chain (<xref ref-type="fig" rid="fig1-2045125319858901">Figure 1</xref>). Another nomenclature uses the
Latin letter <italic>n</italic> instead of the Greek <italic>ω</italic>. Both
nomenclatures are common.</p>
<fig id="fig1-2045125319858901" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>The chemical structure of the two most important n-3 fatty acids,
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).</p>
</caption>
<graphic xlink:href="10.1177_2045125319858901-fig1"></graphic>
</fig>
<p>There are over 30 different PUFAs. In addition to n-3 PUFAs, there are n-5, n-6, n-7,
and n-9 PUFAs. Of these, n-3 and n-6 PUFAs play the most important biological roles,
and the quantitative balance between n-3 and n-6 PUFAs is believed to be a crucial
factor in many disease states (discussed in the following). <xref ref-type="table" rid="table1-2045125319858901">Table 1</xref> gives an overview of biologically
important n-3 and n-6 PUFAs.</p>
<table-wrap id="table1-2045125319858901" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Biologically important n-3 and n-6 polyunsaturated fatty acids (PUFAs).</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_2045125319858901-table1"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Common name</th>
<th align="left" colspan="1" rowspan="1">Lipid name</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">n-3 PUFAs</td>
<td colspan="1" rowspan="1">Alpha-linolenic acid (ALA)<xref ref-type="table-fn" rid="table-fn1-2045125319858901">*</xref></td>
<td colspan="1" rowspan="1">18:3n3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Eicosapentaenoic acid (EPA)<xref ref-type="table-fn" rid="table-fn2-2045125319858901">**</xref></td>
<td colspan="1" rowspan="1">20:5n3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Docosahexaenoic acid (DHA)<xref ref-type="table-fn" rid="table-fn2-2045125319858901">**</xref></td>
<td colspan="1" rowspan="1">22:6n3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">n-6 PUFAs</td>
<td colspan="1" rowspan="1">Linoleic acid (LA)<xref ref-type="table-fn" rid="table-fn1-2045125319858901">*</xref></td>
<td colspan="1" rowspan="1">18:2n6</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Gamma-linolenic acid (GLA)</td>
<td colspan="1" rowspan="1">18:3n6</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Arachidonic acid (AA)</td>
<td colspan="1" rowspan="1">20:4n6</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn1-2045125319858901">
<label>*</label>
<p>Essential fatty acids.</p>
</fn>
<fn id="table-fn2-2045125319858901">
<label>**</label>
<p>Conditionally essential fatty acids.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There are several different n-3 PUFAs, the biologically most relevant ones being
alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA). Humans cannot produce ALA and therefore ALA is one of two
<italic>essential</italic> FAs that must be supplied by diet [the other
essential FA is linoleic acid (LA), which is an n-6 PUFA]. ALA is found in seeds,
nuts, and plant oils. While no major biological effects of ALA on cells or tissues
have been identified so far, its biological value lies mainly in being a substrate
for the synthesis of other PUFAs.<sup><xref ref-type="bibr" rid="bibr9-2045125319858901">9</xref></sup> The human body is not able to synthesize DHA and EPA <italic>de
novo</italic>, but can produce them from ALA. However, this capacity is very limited
and, in addition, subject to polymorphisms of the genes coding for the involved
enzymes (fatty acid desaturase and elongase).<sup><xref ref-type="bibr" rid="bibr10-2045125319858901">10</xref></sup> Reported conversion rates of ALA to EPA are 0.2–6%, and 0.05% or less for
DHA. Women seem to possess a higher conversion capacity than men.<sup><xref ref-type="bibr" rid="bibr9-2045125319858901">9</xref></sup></p>
<p>Since humans can convert only an insufficient proportion of ALA to EPA and DHA, the
latter two are classified as <italic>conditionally essential</italic> FAs.<sup><xref ref-type="bibr" rid="bibr9-2045125319858901">9</xref></sup> Dietary sources of EPA and DHA are fish, shellfish, and meat from marine
mammals, for example, seals and whales. Like humans, these animals do not produce
n-3 PUFAs themselves to a relevant degree. Instead, EPA and DHA are synthesized by
marine algae, which are eaten by small fish that in turn are food for larger
animals.</p>
<p>The phospholipids of the brain’s gray matter and the retina contain high
concentrations of DHA and arachidonic acid (AA, which is an n-6 PUFA), which
supports the notion that long-chain PUFAs play an essential role in the development
and maintenance of proper central nervous system (CNS) function.<sup><xref ref-type="bibr" rid="bibr11-2045125319858901">11</xref><xref ref-type="bibr" rid="bibr12-2045125319858901"></xref><xref ref-type="bibr" rid="bibr13-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr14-2045125319858901">14</xref></sup> Owing to the many double
bonds, PUFAs are more bulky than saturated fatty acids (SFAs; <xref ref-type="fig" rid="fig1-2045125319858901">Figure 1</xref>). When PUFAs instead of SFAs are
incorporated into the phospholipid layer of the cell membrane, the physicochemical
properties of the membrane become altered; it becomes less rigid and more fluid.
More specifically, phase behavior (how a membrane’s mobility changes with
temperature) is shifted to the left, that is, more fluid, while elastic
compressibility (relative volume change/thickness in response to stress),
permeability (passive diffusion of molecules through the membrane), fusion (two
membranes merge into one), flip-flop (transverse diffusion of membrane constituents,
that is, from the outer layer to the inner layer or <italic>vice versa</italic>),
and protein activity become increased.<sup><xref ref-type="bibr" rid="bibr15-2045125319858901">15</xref></sup> Incorporation of n-3 PUFAs into cell membranes also leads to reorganization
of lipid raft formation. Lipid rafts are membrane domains that contain clusters of
receptors and proteins involved in signal transduction. Hence, all these mechanisms
affect the function of membrane proteins, such as receptors, membrane-bound enzymes,
G-proteins, and ion channels, thereby modulating intracellular and intercellular
signaling pathways in neurons and other cell types.<sup><xref ref-type="bibr" rid="bibr16-2045125319858901">16</xref>,<xref ref-type="bibr" rid="bibr17-2045125319858901">17</xref></sup> Of special interest for the
etiology, prophylaxis, and treatment of neuropsychiatric disorders is the
involvement of n-3 PUFAs in the fetal development and later maintenance of
dopaminergic pathways in the brain.<sup><xref ref-type="bibr" rid="bibr18-2045125319858901">18</xref></sup></p>
<p>Another way in which n-3 PUFAs may positively affect CNS functions such as cognition
and behavior is by affecting the gut’s microbiota composition, its fatty acid
composition, and by reducing intestinal inflammation, which in summary affects the
gut–brain axis. This has been demonstrated in both animal and human
studies.<sup><xref ref-type="bibr" rid="bibr19-2045125319858901">19</xref><xref ref-type="bibr" rid="bibr20-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr21-2045125319858901">21</xref></sup></p>
<p>n-3 PUFAs are, apart from being building blocks in cell membranes, biotransformed to
eicosanoids such as prostaglandins, thromboxanes, and leukotrienes, as well as
endocannabinoids and other lipid-based signaling substances that are involved in
many biochemical processes in the body, for example, inflammation and immune
responses. Eicosanoids derived from n-3 PUFAs, such as prostacyclin I3 and
thromboxane A3, are generally considered anti- inflammatory, antithrombotic,
vasodilatory, and antineoplastic. The anti-inflammatory effects of n-3 PUFAS most
probably contribute to their neuroprotective effects in various neuropsychiatric
conditions (see the following). By contrast, signal substances derived from n-6
PUFAs such as AA or LA, for example, prostaglandin E2 or thromboxane A2, have mainly
opposite effects. Therefore, the balance between n-6- and n-3 PUFAs has been
identified as a critical biomarker for chronic disease.<sup><xref ref-type="bibr" rid="bibr22-2045125319858901">22</xref></sup> The WHO has stated that there should be an optimal balance in the dietary
intake constituted by n-6 and n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr23-2045125319858901">23</xref></sup> However, n-6 PUFAs are found in large amounts in most plant oils, and the
consumption of plant oils has exploded in the past decades while fish consumption
has steadily declined.<sup><xref ref-type="bibr" rid="bibr22-2045125319858901">22</xref></sup> Consequently, the Western diet is characterized by an over-supply of n-6
PUFAs, a deficiency in n-3 PUFAs, and, thus, a striking imbalance between these two.<sup><xref ref-type="bibr" rid="bibr22-2045125319858901">22</xref></sup></p>
<p>All PUFAs are highly susceptible to oxidation. Accordingly, oxidative stress in the
body has a large impact on lipid metabolism including PUFAs. Lipid peroxidation
leads to membrane phospholipid degradation, directly affecting cell membrane function.<sup><xref ref-type="bibr" rid="bibr24-2045125319858901">24</xref></sup> Similarly, nutritional supplements that contain PUFAs must be protected by
effective antioxidants. Fish and other sources of marine n-3 PUFAs contain
polyphenols and other compounds that protect n-3 PUFAs from oxidation <italic>in
vivo</italic>. However, these compounds are removed during the production of
commercial n-3 preparations, mainly because they also account for the typical fishy
taste and odor. Therefore, most manufacturers add vitamin E as a fat-soluble
antioxidant. Despite this, studies from different countries have consistently shown
that most n-3 PUFA preparations that are sold over the counter are oxidized (rancid)
to varying degrees.<sup><xref ref-type="bibr" rid="bibr25-2045125319858901">25</xref><xref ref-type="bibr" rid="bibr26-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr27-2045125319858901">27</xref></sup> Obviously,
decomposed n-3 PUFAs have lost their characteristic biological properties. Even
worse, peroxidation products of PUFAs may under certain conditions promote oxidative
stress, a pro-inflammatory environment, DNA damage, and clinical
deterioration.<sup><xref ref-type="bibr" rid="bibr28-2045125319858901">28</xref>,<xref ref-type="bibr" rid="bibr29-2045125319858901">29</xref></sup> Since most interventional clinical studies use ordinary fish
oil capsules, this may be a major reason why some interventional studies did not
find a beneficial effect of n-3 PUFAs or even an increase in clinical symptoms.<sup><xref ref-type="bibr" rid="bibr30-2045125319858901">30</xref></sup></p>
<p>Many authorities and professional societies recommend certain amounts of daily intake
of n-3 PUFAs, but they do not provide corresponding reference ranges for n-3 PUFA
blood levels.<sup><xref ref-type="bibr" rid="bibr31-2045125319858901">31</xref></sup> Nonetheless, free serum n-3 PUFAs, erythrocyte membrane n-3 PUFAs, and whole
blood phospholipid n-3 PUFAs can be measured by many laboratories and used as
biomarkers to estimate the risk for disease and to monitor the efficacy of n-3 PUFA
substitution with a given commercial preparation. The two best documented biomarkers
are (1) the n-3 index, which is the combined percentages of EPA plus DHA measured in
erythrocyte membrane FAs, and (2) the n-6/n-3 ratio, which is the ratio of n-6 FA
and n-3 FA percentages.<sup><xref ref-type="bibr" rid="bibr32-2045125319858901">32</xref></sup> A high n-6/n-3 ratio and a low n-3 index are generally associated with poorer
medical condition. In Western populations, the average n-3 index varies from 2.9% to
7.7% while a value of 8–11% is required for optimal protection against
cardiovascular diseases.<sup><xref ref-type="bibr" rid="bibr33-2045125319858901">33</xref><xref ref-type="bibr" rid="bibr34-2045125319858901"></xref><xref ref-type="bibr" rid="bibr35-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr36-2045125319858901">36</xref></sup> The average n-6/n-3 ratio in
Western countries is 15–21 while a value below 5 is generally recommended.<sup><xref ref-type="bibr" rid="bibr28-2045125319858901">28</xref></sup> The predictive value of the n-6/n-3 ratio has recently been questioned and
the n-3 index has been suggested as a more robust biomarker. It should be noted,
however, that the author of that paper may be biased, as he has commercial interests
related to n-3 index testing.<sup><xref ref-type="bibr" rid="bibr32-2045125319858901">32</xref>,<xref ref-type="bibr" rid="bibr37-2045125319858901">37</xref></sup></p>
<p>The reason why the PUFA status should be measured in red blood cells and not in
plasma is that the plasma fatty acid profile may change within hours, depending on
the type of food and time after intake, while red blood cells have a half-life of
120 days, which provides a much more stable measure of the PUFA content of cell
membranes. Moreover, the PUFA content of red blood cell membranes is highly
correlated to the PUFA content of major organs.<sup><xref ref-type="bibr" rid="bibr38-2045125319858901">38</xref><xref ref-type="bibr" rid="bibr39-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr40-2045125319858901">40</xref></sup></p>
</sec>
<sec id="section3-2045125319858901">
<title>Effects of n-3 PUFAs in various neuropsychiatric disorders</title>
<p>The effects of n-3 PUFAs have been studied in a large variety of neurological and
psychiatric disorders. In the following, a selection of them are discussed.
Additional neuropsychiatric disorders that are not discussed in detail are
summarized at the end of this section.</p>
<sec id="section4-2045125319858901">
<title>Depression</title>
<p>Numerous epidemiological and interventional studies have accumulated strong
evidence for a connection between n-3 PUFA status and depression.<sup><xref ref-type="bibr" rid="bibr41-2045125319858901">41</xref>,<xref ref-type="bibr" rid="bibr42-2045125319858901">42</xref></sup> Low fish
consumption and a low omega-3 index are clearly correlated with a higher risk of
developing a major depression.<sup><xref ref-type="bibr" rid="bibr43-2045125319858901">43</xref><xref ref-type="bibr" rid="bibr44-2045125319858901"></xref><xref ref-type="bibr" rid="bibr45-2045125319858901"></xref><xref ref-type="bibr" rid="bibr46-2045125319858901"></xref><xref ref-type="bibr" rid="bibr47-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr48-2045125319858901">48</xref></sup> Accordingly, an increase
in the omega-3 index reduced the risk and the severity of depressive symptoms in
several clinical studies. One of them found that for each 1% increase in the n-3
index, the risk of developing depression was reduced by 28%.<sup><xref ref-type="bibr" rid="bibr45-2045125319858901">45</xref>,<xref ref-type="bibr" rid="bibr49-2045125319858901">49</xref>,<xref ref-type="bibr" rid="bibr50-2045125319858901">50</xref></sup> This
correlates with findings from clinical studies in nonpsychiatric conditions.<sup><xref ref-type="bibr" rid="bibr33-2045125319858901">33</xref></sup> Depressed patients also exhibit higher n-6/n-3 ratios than nondepressed
controls.<sup><xref ref-type="bibr" rid="bibr50-2045125319858901">50</xref><xref ref-type="bibr" rid="bibr51-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr52-2045125319858901">52</xref></sup></p>
<p>Various studies found an inverse correlation between dietary intake of n-3 PUFAs
and the severity of depressive symptoms including suicidality.<sup><xref ref-type="bibr" rid="bibr28-2045125319858901">28</xref>,<xref ref-type="bibr" rid="bibr48-2045125319858901">48</xref>,<xref ref-type="bibr" rid="bibr52-2045125319858901">52</xref><xref ref-type="bibr" rid="bibr53-2045125319858901"></xref><xref ref-type="bibr" rid="bibr54-2045125319858901"></xref><xref ref-type="bibr" rid="bibr55-2045125319858901"></xref><xref ref-type="bibr" rid="bibr56-2045125319858901"></xref><xref ref-type="bibr" rid="bibr57-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr58-2045125319858901">58</xref></sup> Although some of these
studies produced neutral results, several meta-analyses confirmed the
antidepressant effects of dietary EPA and DHA.<sup><xref ref-type="bibr" rid="bibr59-2045125319858901">59</xref><xref ref-type="bibr" rid="bibr60-2045125319858901"></xref><xref ref-type="bibr" rid="bibr61-2045125319858901"></xref><xref ref-type="bibr" rid="bibr62-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr63-2045125319858901">63</xref></sup> Daily doses between 1 and
3.5 g have produced therapeutic effects.<sup><xref ref-type="bibr" rid="bibr42-2045125319858901">42</xref></sup> It is unclear whether EPA and DHA differ in their antidepressant
efficacy, as each of them independently has been proposed as the strongest
mediator of the beneficial effects of n-3 PUFAs in depression.<sup><xref ref-type="bibr" rid="bibr29-2045125319858901">29</xref>,<xref ref-type="bibr" rid="bibr46-2045125319858901">46</xref>,<xref ref-type="bibr" rid="bibr60-2045125319858901">60</xref>,<xref ref-type="bibr" rid="bibr64-2045125319858901">64</xref>,<xref ref-type="bibr" rid="bibr65-2045125319858901">65</xref></sup>
Interestingly, the DHA amount in blood phospholipids, but not the EPA amount,
distinguished responders from nonresponders in a recent interventional study.<sup><xref ref-type="bibr" rid="bibr66-2045125319858901">66</xref></sup></p>
<p>The efficacy of n-3 PUFAs in special subpopulations such as children,
adolescents, elderly patients with underlying comorbidities, or in related
conditions such as bipolar disorder, is only incompletely studied. Most data
available so far suggest beneficial effects of supplementation with n-3 PUFAs in
these patient groups.<sup><xref ref-type="bibr" rid="bibr29-2045125319858901">29</xref>,<xref ref-type="bibr" rid="bibr67-2045125319858901">67</xref><xref ref-type="bibr" rid="bibr68-2045125319858901"></xref><xref ref-type="bibr" rid="bibr69-2045125319858901"></xref><xref ref-type="bibr" rid="bibr70-2045125319858901"></xref><xref ref-type="bibr" rid="bibr71-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr72-2045125319858901">72</xref></sup></p>
<p>How n-3 PUFAs exert their antidepressant action is not fully understood. At
present, it appears that multiple unspecific mechanisms of action are
responsible. Modulation of G-protein signaling <italic>via</italic> G-protein
coupled receptors and effects on lipid raft formation has been suggested as one
possible mechanism.<sup><xref ref-type="bibr" rid="bibr73-2045125319858901">73</xref></sup> Other mechanisms such as modulation of pro-inflammatory mediators, and
changes in telomerase levels may also play a role.<sup><xref ref-type="bibr" rid="bibr48-2045125319858901">48</xref>,<xref ref-type="bibr" rid="bibr57-2045125319858901">57</xref>,<xref ref-type="bibr" rid="bibr65-2045125319858901">65</xref>,<xref ref-type="bibr" rid="bibr74-2045125319858901">74</xref></sup></p>
</sec>
<sec id="section5-2045125319858901">
<title>Schizophrenia</title>
<p>Schizophrenic patients show a marked depletion of essential FAs, particularly AA
and DHA, in red blood cell membranes. These two FAs are the most abundant FAs in
the human brain, which suggests that they play a crucial role in the function of
the CNS.<sup><xref ref-type="bibr" rid="bibr11-2045125319858901">11</xref><xref ref-type="bibr" rid="bibr12-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr13-2045125319858901">13</xref></sup> Accumulating evidence from
experimental and clinical studies has led to the ‘membrane hypothesis’, which
postulates dietary-related changes in PUFA-dependent membrane function as a
major pathophysiologic mechanism in schizophrenia.<sup><xref ref-type="bibr" rid="bibr75-2045125319858901">75</xref>,<xref ref-type="bibr" rid="bibr76-2045125319858901">76</xref></sup> Accordingly, diet changes
that lead to increased membrane levels of n3-PUFAs can have significant effects
on schizophrenic symptoms.<sup><xref ref-type="bibr" rid="bibr77-2045125319858901">77</xref></sup></p>
<p>Several randomized, placebo-controlled clinical trials have studied the efficacy
of n-3 PUFA supplementation in schizophrenia. While some yielded positive
results,<sup><xref ref-type="bibr" rid="bibr78-2045125319858901">78</xref><xref ref-type="bibr" rid="bibr79-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr80-2045125319858901">80</xref></sup> others
found partial efficacy such as reduced need for antipsychotic
medication,<sup><xref ref-type="bibr" rid="bibr81-2045125319858901">81</xref>,<xref ref-type="bibr" rid="bibr82-2045125319858901">82</xref></sup> or no beneficial effects at all.<sup><xref ref-type="bibr" rid="bibr30-2045125319858901">30</xref>,<xref ref-type="bibr" rid="bibr83-2045125319858901">83</xref></sup> However, the observation
time in most studies was only 8–12 weeks and as mentioned earlier in this
article, sustained changes in membrane function may take longer time to develop.
The only long-term study so far, a 6-month, randomized, placebo-controlled trial
in first-episode schizophrenic patients, found a significantly greater decrease
in the intensity of symptoms and an improved level of functioning in the n-3
group than in the placebo group.<sup><xref ref-type="bibr" rid="bibr84-2045125319858901">84</xref></sup></p>
<p>Disturbances in cortical membrane FA homeostasis have been identified as a
pathological aspect of schizophrenia, which is one of several possible
explanations for the efficacy of n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr75-2045125319858901">75</xref>,<xref ref-type="bibr" rid="bibr76-2045125319858901">76</xref>,<xref ref-type="bibr" rid="bibr85-2045125319858901">85</xref></sup> Beyond membrane-related
effects on neuronal cell signaling pathways, n-3 PUFAs may act through
additional mechanisms, for example, modulation of dopaminergic pathways in the
mesolimbic system.<sup><xref ref-type="bibr" rid="bibr18-2045125319858901">18</xref></sup> In an <italic>in vitro</italic> model mimicking the involvement of viral
infection in the development of neuropsychiatric disorders, n-3 PUFAs showed
significant neuroprotective effects.<sup><xref ref-type="bibr" rid="bibr86-2045125319858901">86</xref></sup> In addition, clinical studies in schizophrenic patients found that n-3
PUFA substitution leads to an increase in telomerase levels as well as a
reduction in oxidative stress.<sup><xref ref-type="bibr" rid="bibr84-2045125319858901">84</xref>,<xref ref-type="bibr" rid="bibr87-2045125319858901">87</xref>,<xref ref-type="bibr" rid="bibr88-2045125319858901">88</xref></sup></p>
</sec>
<sec id="section6-2045125319858901">
<title>ADHD</title>
<p>It is well established that dietary depletion of n-3 PUFAs during fetal
development and early childhood may have adverse effects on brain development,
neurodevelopmental outcomes, and cognitive health.<sup><xref ref-type="bibr" rid="bibr54-2045125319858901">54</xref>,<xref ref-type="bibr" rid="bibr89-2045125319858901">89</xref>,<xref ref-type="bibr" rid="bibr90-2045125319858901">90</xref></sup> For example, low maternal
intake of n-3 fatty acids during pregnancy is correlated with lower verbal
intelligence, attention deficit hyperactivity disorder (ADHD), dyslexia,
dyspraxia, autism, and impaired social behavior in the child.<sup><xref ref-type="bibr" rid="bibr89-2045125319858901">89</xref>,<xref ref-type="bibr" rid="bibr91-2045125319858901">91</xref><xref ref-type="bibr" rid="bibr92-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr93-2045125319858901">93</xref></sup></p>
<p>Epidemiological studies found that children with ADHD have lower blood levels of
n-3 PUFAs than controls.<sup><xref ref-type="bibr" rid="bibr93-2045125319858901">93</xref><xref ref-type="bibr" rid="bibr94-2045125319858901"></xref><xref ref-type="bibr" rid="bibr95-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr96-2045125319858901">96</xref></sup> Accordingly, several
randomized, placebo-controlled interventional trials reported positive effects
of dietary supplementation with n-3 PUFAs in ADHD.<sup><xref ref-type="bibr" rid="bibr94-2045125319858901">94</xref>,<xref ref-type="bibr" rid="bibr95-2045125319858901">95</xref>,<xref ref-type="bibr" rid="bibr97-2045125319858901">97</xref><xref ref-type="bibr" rid="bibr98-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr99-2045125319858901">99</xref></sup> However, other trials
found only small or no therapeutic effects. Hence, some meta-analyses stated
that there is evidence for n-3 PUFAs as a supplement to established therapies
while others concluded that the currently available evidence is
inconclusive.<sup><xref ref-type="bibr" rid="bibr94-2045125319858901">94</xref>,<xref ref-type="bibr" rid="bibr100-2045125319858901">100</xref><xref ref-type="bibr" rid="bibr101-2045125319858901"></xref><xref ref-type="bibr" rid="bibr102-2045125319858901"></xref><xref ref-type="bibr" rid="bibr103-2045125319858901"></xref><xref ref-type="bibr" rid="bibr104-2045125319858901"></xref><xref ref-type="bibr" rid="bibr105-2045125319858901"></xref><xref ref-type="bibr" rid="bibr106-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr107-2045125319858901">107</xref></sup> Major reasons for these
contradictory conclusions are different selection of studies, small sample
sizes, variability of inclusion criteria, variability of the type and dosage of
supplementation, short follow-up times, and different cognitive and behavioral
outcome parameters.<sup><xref ref-type="bibr" rid="bibr101-2045125319858901">101</xref>,<xref ref-type="bibr" rid="bibr102-2045125319858901">102</xref>,<xref ref-type="bibr" rid="bibr105-2045125319858901">105</xref></sup> Moreover, some studies that used multiple outcome
parameters observed therapeutic effects in some but not all of them.</p>
<p>While the pathophysiology of ADHD is not fully understood, it is generally
accepted that brain dopaminergic and noradrenergic systems play a central role.
This hypothesis is supported by the clinical effectiveness of medicines such as
methylphenidate and amphetamine. In animal experiments, n-3 PUFA depletion
induced symptoms that mimic ADHD in humans, while symptom severity was inversely
correlated with dietary n-3 PUFA intake. The significance of n-3 PUFAs for the
regulation of dopaminergic pathways in ADHD has recently been reviewed.<sup><xref ref-type="bibr" rid="bibr18-2045125319858901">18</xref></sup></p>
</sec>
<sec id="section7-2045125319858901">
<title>PTSD</title>
<p>It has long been known that both physical and psychological stress are associated
with altered blood levels of free fatty acids including long-chain
PUFAs.<sup><xref ref-type="bibr" rid="bibr108-2045125319858901">108</xref>,<xref ref-type="bibr" rid="bibr109-2045125319858901">109</xref></sup> Cross-sectional studies reported lower n-3 PUFA blood
levels in patients with PTSD than in healthy controls.<sup><xref ref-type="bibr" rid="bibr110-2045125319858901">110</xref>,<xref ref-type="bibr" rid="bibr111-2045125319858901">111</xref></sup> Similarly, longitudinal
studies found an inverse relation between blood levels of n-3 PUFAs and the risk
of developing PTSD after accidental injury.<sup><xref ref-type="bibr" rid="bibr112-2045125319858901">112</xref>,<xref ref-type="bibr" rid="bibr113-2045125319858901">113</xref></sup></p>
<p>However, only a few clinical trials examined possible effects of supplementation
with n-3 PUFAs on post-traumatic stress disorder (PTSD), and they produced mixed
results. While one study found that EPA but not DHA reduces the risk of
developing PTSD in patients with accidental injury,<sup><xref ref-type="bibr" rid="bibr114-2045125319858901">114</xref></sup> another study found ameliorated psychophysiological stress responses
after combined supplementation with a high dose of DHA + a low dose of EPA.<sup><xref ref-type="bibr" rid="bibr115-2045125319858901">115</xref></sup> A study in survivors of the great earthquake in Japan 2011 found an
effect of 1568 mg DHA + 157 mg EPA in women, but not in men.<sup><xref ref-type="bibr" rid="bibr116-2045125319858901">116</xref></sup> Further clinical research is clearly needed.</p>
<p>Different mechanisms could mediate possible effects of n-3 PUFAs in PTSD and
other stress-related conditions. Since PTSD is associated with increased
interleukin 6, interleukin 1β, tumor necrosis factor alpha (TNFα), and
interferon γ levels, it has been suggested that the expression of these
cytokines may be normalized by the anti-inflammatory and neuroprotective actions
of n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr117-2045125319858901">117</xref></sup> This hypothesis is supported by experimental findings.<sup><xref ref-type="bibr" rid="bibr118-2045125319858901">118</xref></sup> Another, more specific mechanism may be an increase in brain-derived
neurotrophic factor (BDNF) induced by n-3 PUFAs, which leads to induction of
hippocampal neurogenesis by which fear-related memory might be
cleared.<sup><xref ref-type="bibr" rid="bibr119-2045125319858901">119</xref><xref ref-type="bibr" rid="bibr120-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr121-2045125319858901">121</xref></sup> A more
recent hypothesis assumes a role of the n-3 PUFA-derived endocannabinoids
2-docosahexaenoylglycerol (2-DHG) and docosahexaenoylethanolamine (DHA-EA) in
reducing psychological distress.<sup><xref ref-type="bibr" rid="bibr122-2045125319858901">122</xref></sup></p>
</sec>
<sec id="section8-2045125319858901">
<title>Dementia</title>
<p>The clinical efficacy of established medications for Alzheimer’s disease (AD) and
other dementias is weak, and new treatment options are urgently warranted. A
large body of evidence suggests a positive correlation between n-3 PUFAs and
cognition, and most (but not all) interventional studies reported beneficial
effects of n-3 PUFAs on cognitive outcome and quality of life in patients with
AD, especially with early stage AD and mild cognitive impariment.<sup><xref ref-type="bibr" rid="bibr20-2045125319858901">20</xref>,<xref ref-type="bibr" rid="bibr123-2045125319858901">123</xref><xref ref-type="bibr" rid="bibr124-2045125319858901"></xref><xref ref-type="bibr" rid="bibr125-2045125319858901"></xref><xref ref-type="bibr" rid="bibr126-2045125319858901"></xref><xref ref-type="bibr" rid="bibr127-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr128-2045125319858901">128</xref></sup> While some
interventional studies reported neutral results, a recent meta-analysis by Zhang
<italic>et al.</italic> found that n-3 PUFAs from fishery products are
associated with a lower risk of cognitive decline in AD patients.<sup><xref ref-type="bibr" rid="bibr129-2045125319858901">129</xref></sup> This is supported by a study in healthy subjects where both the n-3 index
and the n-6/n-3 ratio were correlated with cognitive function as well as
hippocampal and total brain volume.<sup><xref ref-type="bibr" rid="bibr130-2045125319858901">130</xref>,<xref ref-type="bibr" rid="bibr131-2045125319858901">131</xref></sup></p>
<p>Experimental evidence implies biological plausibility for beneficial effects of
n-3 PUFAs in dementia. Antioxidant actions, enhanced brain plasticity, and other
mechanisms that are more directly related to the specific pathology displayed in
dementia, such as anti-inflammatory, anti- amyloid and anti-tau effects, have
been demonstrated.<sup><xref ref-type="bibr" rid="bibr132-2045125319858901">132</xref><xref ref-type="bibr" rid="bibr133-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr134-2045125319858901">134</xref></sup> DHA may
have stronger neuroprotective properties than EPA as DHA-deficiency is highly
correlated with cortical and hippocampal atrophy.<sup><xref ref-type="bibr" rid="bibr135-2045125319858901">135</xref>,<xref ref-type="bibr" rid="bibr136-2045125319858901">136</xref></sup> Experimental data also
show that DHA regulates apoptotic processes and the level of Aβ-induced lipid
peroxides, which has positive effects on the survival of neurons.<sup><xref ref-type="bibr" rid="bibr137-2045125319858901">137</xref></sup> In addition, DHA increases dendrite density and reduces beta amyloid and
tau protein load.<sup><xref ref-type="bibr" rid="bibr138-2045125319858901">138</xref><xref ref-type="bibr" rid="bibr139-2045125319858901"></xref><xref ref-type="bibr" rid="bibr140-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr141-2045125319858901">141</xref></sup></p>
<p>In addition to these mechanisms, n-3 PUFAs may ameliorate cognitive dysfunction
via indirect effects. Both AD and vascular dementia are associated with
cardiovascular events such as microinfarctions in the brain, and it has been
shown that prevention of cardiovascular morbidity with n-3 PUFAs has beneficial
effects on cognitive function.<sup><xref ref-type="bibr" rid="bibr142-2045125319858901">142</xref>,<xref ref-type="bibr" rid="bibr143-2045125319858901">143</xref></sup></p>
<p>Factors that might explain the mixed results of clinical studies on n-3 PUFAs in
dementia are the large variations in study design (e.g. RCTs
<italic>versus</italic> epidemiological studies), study populations,
observation times and follow-up periods, variations in n-3 dosages, different
biomarkers for fatty acid status, different cognitive outcome parameters as well
as different (and partly low) sensitivity in the neuropsychological tests.
Notably, it has been suggested that n-3 PUFAs may exert their most significant
effects on cognition before disease onset. This is of special importance in AD
which is a disease that probably starts decades before clinical symptoms become
overt.<sup><xref ref-type="bibr" rid="bibr131-2045125319858901">131</xref>,<xref ref-type="bibr" rid="bibr144-2045125319858901">144</xref></sup></p>
</sec>
<sec id="section9-2045125319858901">
<title>Parkinson’s disease</title>
<p>After AD, Parkinson’s disease (PD) is the second most common neurodegenerative
disorder with a prevalence of about 2% in people over 65 years.<sup><xref ref-type="bibr" rid="bibr145-2045125319858901">145</xref></sup> While the etiology of PD is still not fully understood, its
pathophysiology is well studied and involves dysfunction of the mitochondria and
inflammatory and oxidative stress reactions.<sup><xref ref-type="bibr" rid="bibr146-2045125319858901">146</xref><xref ref-type="bibr" rid="bibr147-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr148-2045125319858901">148</xref></sup> Despite this knowledge,
the standard pharmacological approach to treat PD is still more or less limited
to enhancing dopaminergic signaling. However, dopaminergic medications may lose
effect over time and can induce serious side effects.<sup><xref ref-type="bibr" rid="bibr149-2045125319858901">149</xref>,<xref ref-type="bibr" rid="bibr150-2045125319858901">150</xref></sup></p>
<p>Only few clinical studies examined n-3 PUFAs in PD. All but one reported
beneficial effect. Observational studies found a correlation between higher
intake of n-3 PUFAs from fish and lower prevalence of PD.<sup><xref ref-type="bibr" rid="bibr151-2045125319858901">151</xref>,<xref ref-type="bibr" rid="bibr152-2045125319858901">152</xref></sup> In the
Rotterdam Study, a prospective population-based cohort study of 5289 subjects,
each SD increase of energy-adjusted intake of PUFAs reduced the risk of
developing PD by 34 %.<sup><xref ref-type="bibr" rid="bibr153-2045125319858901">153</xref></sup> A randomized, double-blind placebo-controlled trial found that
supplementation with n-3 PUFAs improved clinical symptomatology in PD patients,
as indicated by a decrease in the average Unified Parkinson’s Disease Rating
Scale score.<sup><xref ref-type="bibr" rid="bibr154-2045125319858901">154</xref></sup> A case–control study, however, found that dietary intake of n-3 PUFAs was
not predictive for the risk of developing PD.<sup><xref ref-type="bibr" rid="bibr155-2045125319858901">155</xref></sup></p>
<p>Part of the positive effects of n-3 PUFAs on PD is probably due to their
neuroprotective properties, since oxidative stress and neuroinflammation are
ameliorated by n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr156-2045125319858901">156</xref></sup> Indeed, a clinical study found that supplementation with n-3 PUFAs
decreased C-reactive protein and increased glutathione concentrations as well as
total antioxidant capacity.<sup><xref ref-type="bibr" rid="bibr154-2045125319858901">154</xref></sup> These results are supported by experimental findings demonstrating a
reduction of inducible nitric oxide synthase activity in the CNS and increased
levels of BDNF after supplementation with n-3 PUFAs.<sup><xref ref-type="bibr" rid="bibr120-2045125319858901">120</xref>,<xref ref-type="bibr" rid="bibr157-2045125319858901">157</xref>,<xref ref-type="bibr" rid="bibr158-2045125319858901">158</xref></sup> Apart from
neuroprotective effects, n-3 PUFAs may enhance dopaminergic signal transduction
through different mechanisms.<sup><xref ref-type="bibr" rid="bibr18-2045125319858901">18</xref></sup></p>
</sec>
</sec>
<sec id="section10-2045125319858901">
<title>Other neurological and psychiatric disorders</title>
<p>In addition to the conditions discussed above, the effects of supplementation with
n-3 PUFAs have been clinically studied in other neuropsychiatric disorders, such as
epilepsy,<sup><xref ref-type="bibr" rid="bibr159-2045125319858901">159</xref><xref ref-type="bibr" rid="bibr160-2045125319858901"></xref><xref ref-type="bibr" rid="bibr161-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr162-2045125319858901">162</xref></sup> multiple
sclerosis,<sup><xref ref-type="bibr" rid="bibr163-2045125319858901">163</xref><xref ref-type="bibr" rid="bibr164-2045125319858901"></xref><xref ref-type="bibr" rid="bibr165-2045125319858901"></xref><xref ref-type="bibr" rid="bibr166-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr167-2045125319858901">167</xref></sup> bipolar disorder,<sup><xref ref-type="bibr" rid="bibr168-2045125319858901">168</xref><xref ref-type="bibr" rid="bibr169-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr170-2045125319858901">170</xref></sup> anorexia nervosa,<sup><xref ref-type="bibr" rid="bibr171-2045125319858901">171</xref><xref ref-type="bibr" rid="bibr172-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr173-2045125319858901">173</xref></sup> borderline personality
disorder,<sup><xref ref-type="bibr" rid="bibr174-2045125319858901">174</xref><xref ref-type="bibr" rid="bibr175-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr176-2045125319858901">176</xref></sup> and autism
spectrum disorders.<sup><xref ref-type="bibr" rid="bibr177-2045125319858901">177</xref><xref ref-type="bibr" rid="bibr178-2045125319858901"></xref><xref ref-type="bibr" rid="bibr179-2045125319858901"></xref><xref ref-type="bibr" rid="bibr180-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr181-2045125319858901">181</xref></sup> Apart from these systematic
clinical trials, numerous case reports have been published for these and even more
neuropsychiatric conditions including rare metabolic diseases such as Zellweger syndrome.<sup><xref ref-type="bibr" rid="bibr39-2045125319858901">39</xref></sup> The majority of these interventions reported beneficial effects of
supplementation with n-3 PUFAs. These findings are supported by numerous
epidemiological studies that found strong evidence for an inverse relation between
dietary n-3 PUFA intake/blood n-3 status and the prevalence and severity of the
conditions mentioned above.<sup><xref ref-type="bibr" rid="bibr182-2045125319858901">182</xref><xref ref-type="bibr" rid="bibr183-2045125319858901"></xref><xref ref-type="bibr" rid="bibr184-2045125319858901"></xref><xref ref-type="bibr" rid="bibr185-2045125319858901"></xref><xref ref-type="bibr" rid="bibr186-2045125319858901"></xref><xref ref-type="bibr" rid="bibr187-2045125319858901"></xref><xref ref-type="bibr" rid="bibr188-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr189-2045125319858901">189</xref></sup></p>
</sec>
<sec id="section11-2045125319858901">
<title>Safety of n-3 PUFAs</title>
<p>Most of the clinical studies cited in this paper did either not report any clinically
significant adverse effects or no difference <italic>versus</italic> placebo. Few
studies reported mild to moderate adverse reactions, mainly nausea or loose stools,
especially with high doses.</p>
<p>A much-debated study in men with prostate cancer, the SELECT trial, reported that
higher plasma omega-3 fatty acid levels were associated with increased risk for
developing prostate cancer.<sup><xref ref-type="bibr" rid="bibr190-2045125319858901">190</xref></sup> However, several comments on that study pointed out that this conclusion was
inappropriate and not supported by study data. Moreover, other studies found
opposite effects of n-3 PUFAs on prostate cancer.<sup><xref ref-type="bibr" rid="bibr191-2045125319858901">191</xref><xref ref-type="bibr" rid="bibr192-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr193-2045125319858901">193</xref></sup></p>
<p>Although it has been postulated that n-3 PUFAs may increase LDL cholesterol, affect
glucose metabolism and prolong bleeding time, recent studies as well as reviews and
meta-analyses do not support this.<sup><xref ref-type="bibr" rid="bibr194-2045125319858901">194</xref><xref ref-type="bibr" rid="bibr195-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr196-2045125319858901">196</xref></sup> Given the widespread use of
n-3 supplements and the experience from a large number of clinical studies, it must
be concluded that these potential effects may gain clinical significance only in
rare cases. Accordingly, the United States FDA has ruled that the daily intake of up
to 3 g of n-3 PUFAs is generally recognized as safe (GRAS).<sup><xref ref-type="bibr" rid="bibr197-2045125319858901">197</xref></sup> This ruling took into consideration the postulated effects on glucose
metabolism, bleeding, and low-density lipoprotein (LDL) cholesterol. Similarly, the
European Union’s EFSA Panel on Dietetic Products Nutrition and Allergies concluded
that supplemental intake of EPA and DHA at combined doses up to 5 g per day, and
supplemental intakes of EPA alone up to 1.8 g per day, do not raise safety concerns
for adults.<sup><xref ref-type="bibr" rid="bibr198-2045125319858901">198</xref></sup></p>
</sec>
<sec id="section12-2045125319858901">
<title>Recommendations for future research</title>
<p>Most clinical trials that assessed the effect of dietary supplementation with n-3
PUFAs in neuropsychiatric conditions yielded positive results. However, a
considerable number of studies produced neutral or even negative results. The
conflicting findings may be attributed to several reasons.</p>
<list id="list1-2045125319858901" list-type="order">
<list-item>
<p>Almost all interventional studies used fish oil capsules. That may have
seriously distorted the results from these studies since most commercial n-3
preparations are oxidized (rancid) to varying degrees.<sup><xref ref-type="bibr" rid="bibr25-2045125319858901">25</xref><xref ref-type="bibr" rid="bibr26-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr27-2045125319858901">27</xref></sup> Future
studies using such capsules should therefore report the degree of oxidation
in the preparations used, for example, by stating the peroxide value (PV),
the anisidine value (AV), or the total oxidation value (TOTOX).</p>
</list-item>
<list-item>
<p>Omega-3 preparations are manufactured from different natural sources,
containing different amounts of n-3 PUFAs, different DHA:EPA-ratios and
different chemical composition of these FAs (mostly as ethyl esters, but
also as triglycerides, diglycerides, monoglycerides, phospholipids, or free
carboxylic acids) as well as different types and amounts of antioxidants
(e.g. various types of tocopherols, astaxanthin, etc.). These different
formulations naturally lead to differences in bioavailability,
susceptibility for oxidation, and biological activity.<sup><xref ref-type="bibr" rid="bibr199-2045125319858901">199</xref><xref ref-type="bibr" rid="bibr200-2045125319858901"></xref><xref ref-type="bibr" rid="bibr201-2045125319858901"></xref><xref ref-type="bibr" rid="bibr202-2045125319858901"></xref>–<xref ref-type="bibr" rid="bibr203-2045125319858901">203</xref></sup>
Being classified as food or food supplements, commercial n-3 products are
not subject to bioequivalence requirements or other stringent forms of
pharmaceutical/pharmacological standardization the way licensed medical
drugs are. Disregarding the fact that all these n-3 preparations are not
pharmaceutically and biologically equivalent represents a major weakness of
clinical trials and, particularly, meta-analyses of these trials.</p>
</list-item>
<list-item>
<p>Most clinical studies used fixed doses and did not measure blood levels of
n-3 PUFAs. Owing to the uncertainties inferred by varying degrees of
oxidation and varying bioavailability (see above), future clinical studies
should rather use individual dosing guided by the n-3 index and the n-6/n-3
ratio. Target ranges for these biomarkers should be defined before study
start. A striking example for a failed clinical study and the necessity of
defining target ranges is the recently published VITAL study.<sup><xref ref-type="bibr" rid="bibr204-2045125319858901">204</xref></sup> After 1 year of treatment, the average n-3 index had risen from 2.1%
to 4.1% and the researchers did not find a cardioprotective effect of n-3
PUFAs. It is well documented that this index must be at least 8% to obtain a
cardioprotective effect, while an index below 4% is classified as ‘high
risk’ for cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr33-2045125319858901">33</xref></sup> Consequently, the study merely confirmed the previous knowledge that
an n-3 index below 8% does not provide cardioprotection.</p>
</list-item>
<list-item>
<p>While an effect of n-3 PUFA substitution on the synthesis of lipid-based
signaling substances and other cytokines usually can be seen after a few
days (due to the short biological half-life of these compounds), their
incorporation into cell membranes and the onset of related biological
effects may take longer time, depending on the turnover rate of these cells,
the phospholipid-layer of their cell membrane and of the incorporated
proteins. Thus, the length of the observation period is crucial, and 8 weeks
may not be enough in all cases. For the same reason, n-3 PUFAs appear less
suitable as acute treatment of neuropsychiatric disorders, but more useful
for long-term prevention.</p>
</list-item>
</list>
</sec>
<sec id="section13-2045125319858901" sec-type="conclusions">
<title>Conclusion</title>
<p>A connection between nutritional factors and neuropsychiatric disorders should be
regarded as established. Numerous epidemiological studies have shown a strong
correlation between low n-3 PUFA status and higher prevalence and severity of
different neuropsychiatric disorders. Accordingly, many interventional studies that
assessed the efficacy of n-3 PUFA supplementation in different neuropsychiatric
disorders have found positive effects. A large body of experimental data provides a
solid biological and pharmacological basis for these findings. At present, n-3 PUFAs
appear to be more useful in long-term preventive approaches rather than treatment of
acute episodes. However, not all clinical studies found beneficial effects. Possible
reasons for conflicting findings have been discussed in this review, and future
clinical studies as well as meta-analyses of such studies should address them.
Measurement of n-3 PUFAs in blood for diagnostic purposes, risk assessment, and
therapeutic drug monitoring is cheap and already available at many laboratories. The
use of n-3 PUFAs as a therapeutic option in the treatment of neurological and
psychiatric disorders may be still in its infancy, but their therapeutic potential,
favorable safety profile, ease of administration, and low treatment costs are
promising. The increasing number of clinical studies and other research papers
suggests that supplementation with n-3 PUFAs may play a greater role in the future
treatment of neuropsychiatric disorders.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or
publication of this article.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest statement:</bold> AR has received speaker’s honoraria and consultant fees from GlaxoSmithKline,
UCB, and Zinzino. HL has nothing to declare.</p>
</fn>
<fn fn-type="other">
<p><bold>Ethical Statement:</bold> Our study did not require an ethical board approval because it did not contain
human or animal trials.</p>
</fn>
<fn fn-type="other">
<p><bold>ORCID iD:</bold> Arne Reimers <inline-graphic xlink:href="10.1177_2045125319858901-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6286-554X">https://orcid.org/0000-0002-6286-554X</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2045125319858901">
<label>1</label>
<mixed-citation publication-type="journal">
<collab>Global Burden of Disease Study</collab>. <article-title>Global,
regional, and national disability-adjusted life-years (DALYs) for 359
diseases and injuries and healthy life expectancy (HALE) for 195 countries
and territories, 1990–2017: a systematic analysis for the Global Burden of
Disease Study 2017</article-title>. <source/>Lancet
<year>2018</year>; <volume>392</volume>:
<fpage>1859</fpage>–<lpage>1922</lpage>.<pub-id pub-id-type="pmid">30415748</pub-id></mixed-citation>
</ref>
<ref id="bibr2-2045125319858901">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>JS</given-names></name><name><surname>Hiles</surname><given-names>S</given-names></name><name><surname>Bisquera</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>A systematic review and meta-analysis of dietary
patterns and depression in community-dwelling adults</article-title>.
<source/>Am J Clin Nutr
<year>2014</year>; <volume>99</volume>:
<fpage>181</fpage>–<lpage>197</lpage>.<pub-id pub-id-type="pmid">24196402</pub-id></mixed-citation>
</ref>
<ref id="bibr3-2045125319858901">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Logan</surname><given-names>AC</given-names></name><name><surname>Akbaraly</surname><given-names>TN</given-names></name><etal>et al</etal></person-group>
<article-title>Nutritional medicine as mainstream in
psychiatry</article-title>. <source/>Lancet Psychiatry
<year>2015</year>; <volume>2</volume>:
<fpage>271</fpage>–<lpage>274</lpage>.<pub-id pub-id-type="pmid">26359904</pub-id></mixed-citation>
</ref>
<ref id="bibr4-2045125319858901">
<label>4</label>
<mixed-citation publication-type="book">
<collab>Mental Health Foundation</collab>. <source/>Feeding Minds: The Impact of
Food on Mental Health. <publisher-name>Mental Health
Foundation</publisher-name>, <year>2006</year>.</mixed-citation>
</ref>
<ref id="bibr5-2045125319858901">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Logan</surname><given-names>AC</given-names></name><name><surname>Akbaraly</surname><given-names>TN</given-names></name><etal>et al</etal></person-group>
<article-title>International Society for Nutritional Psychiatry
Research consensus position statement: nutritional medicine in modern
psychiatry</article-title>. <source/>World Psychiatry
<year>2015</year>; <volume>14</volume>:
<fpage>370</fpage>–<lpage>371</lpage>.<pub-id pub-id-type="pmid">26407799</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2045125319858901">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bang</surname><given-names>HO</given-names></name><name><surname>Dyerberg</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>AB.</given-names></name></person-group>
<article-title>Plasma lipid and lipoprotein pattern in Greenlandic West-coast
Eskimos</article-title>. <source/>Lancet
<year>1971</year>; <volume>1</volume>:
<fpage>1143</fpage>–<lpage>1145</lpage>.<pub-id pub-id-type="pmid">4102857</pub-id></mixed-citation>
</ref>
<ref id="bibr7-2045125319858901">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGrath-Hanna</surname><given-names>NK</given-names></name><name><surname>Greene</surname><given-names>DM</given-names></name><name><surname>Tavernier</surname><given-names>RJ</given-names></name><etal>et al</etal></person-group>
<article-title>Diet and mental health in the Arctic: is diet an
important risk factor for mental health in circumpolar peoples? A
review</article-title>. <source/>Int J Circumpolar Health
<year>2003</year>; <volume>62</volume>:
<fpage>228</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">14594198</pub-id></mixed-citation>
</ref>
<ref id="bibr8-2045125319858901">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yehuda</surname><given-names>S.</given-names></name></person-group>
<article-title>Omega-6/omega-3 ratio and brain-related
functions</article-title>. <source/>World Rev Nutr Diet
<year>2003</year>; <volume>92</volume>:
<fpage>37</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">14579682</pub-id></mixed-citation>
</ref>
<ref id="bibr9-2045125319858901">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burdge</surname><given-names>GC.</given-names></name></person-group>
<article-title>Metabolism of alpha-linolenic acid in humans</article-title>.
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2006</year>; <volume>75</volume>:
<fpage>161</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">16828546</pub-id></mixed-citation>
</ref>
<ref id="bibr10-2045125319858901">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH.</given-names></name></person-group>
<article-title>Omega-3 fatty acids: new insights into the pharmacology and
biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic
acid</article-title>. <source/>Curr Opin Lipidol
<year>2013</year>; <volume>24</volume>:
<fpage>467</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">24184945</pub-id></mixed-citation>
</ref>
<ref id="bibr11-2045125319858901">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Innis</surname><given-names>SM.</given-names></name></person-group>
<article-title>Dietary omega 3 fatty acids and the developing
brain</article-title>. <source/>Brain Res
<year>2008</year>; <volume>1237</volume>:
<fpage>35</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">18789910</pub-id></mixed-citation>
</ref>
<ref id="bibr12-2045125319858901">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chalon</surname><given-names>S</given-names></name><name><surname>Vancassel</surname><given-names>S</given-names></name><name><surname>Zimmer</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Polyunsaturated fatty acids and cerebral
function: focus on monoaminergic neurotransmission</article-title>.
<source/>Lipids
<year>2001</year>; <volume>36</volume>:
<fpage>937</fpage>–<lpage>944</lpage>.<pub-id pub-id-type="pmid">11724466</pub-id></mixed-citation>
</ref>
<ref id="bibr13-2045125319858901">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yehuda</surname><given-names>S.</given-names></name></person-group>
<article-title>Omega-6/omega-3 ratio and brain-related
functions</article-title>. <source/>World Rev Nutr Diet
<year>2003</year>; <volume>92</volume>:
<fpage>37</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">14579682</pub-id></mixed-citation>
</ref>
<ref id="bibr14-2045125319858901">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>JK</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>Lemaitre</surname><given-names>RN</given-names></name><etal>et al</etal></person-group>
<article-title>Circulating omega-3 polyunsaturated fatty acids
and subclinical brain abnormalities on MRI in older adults: the
Cardiovascular Health Study</article-title>. <source/>J Am Heart
Assoc
<year>2013</year>; <volume>2</volume>: <fpage>e000305</fpage>.<pub-id pub-id-type="pmid">24113325</pub-id></mixed-citation>
</ref>
<ref id="bibr15-2045125319858901">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stillwell</surname><given-names>W</given-names></name><name><surname>Wassall</surname><given-names>SR.</given-names></name></person-group>
<article-title>Docosahexaenoic acid: membrane properties of a unique fatty
acid</article-title>. <source/>Chem Phys Lipids
<year>2003</year>; <volume>126</volume>:
<fpage>1</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">14580707</pub-id></mixed-citation>
</ref>
<ref id="bibr16-2045125319858901">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gueguinou</surname><given-names>M</given-names></name><name><surname>Gambade</surname><given-names>A</given-names></name><name><surname>Felix</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Lipid rafts, KCa/ClCa/Ca2+ channel complexes and
EGFR signaling: Novel targets to reduce tumor development by
lipids?</article-title>
<source/>Biochim Biophys Acta
<year>2015</year>; <volume>1848</volume>:
<fpage>2603</fpage>–<lpage>2620</lpage>.<pub-id pub-id-type="pmid">25450343</pub-id></mixed-citation>
</ref>
<ref id="bibr17-2045125319858901">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turk</surname><given-names>HF</given-names></name><name><surname>Chapkin</surname><given-names>RS.</given-names></name></person-group>
<article-title>Membrane lipid raft organization is uniquely modified by n-3
polyunsaturated fatty acids</article-title>. <source/>Prostaglandins Leukot
Essent Fatty Acids
<year>2013</year>; <volume>88</volume>:
<fpage>43</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">22515942</pub-id></mixed-citation>
</ref>
<ref id="bibr18-2045125319858901">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Healy-Stoffel</surname><given-names>M</given-names></name><name><surname>Levant</surname><given-names>B.</given-names></name></person-group>
<article-title>N-3 (Omega-3) fatty acids: effects on brain dopamine systems and
potential role in the etiology and treatment of neuropsychiatric
disorders</article-title>. <source/>CNS Neurol Disord Drug Targets
<year>2018</year>; <volume>17</volume>:
<fpage>216</fpage>–<lpage>232</lpage>.<pub-id pub-id-type="pmid">29651972</pub-id></mixed-citation>
</ref>
<ref id="bibr19-2045125319858901">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costantini</surname><given-names>L</given-names></name><name><surname>Molinari</surname><given-names>R</given-names></name><name><surname>Farinon</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Impact of omega-3 fatty acids on the gut
microbiota</article-title>. <source/>Int J Mol Sci
<year>2017</year>; <fpage>18</fpage>.</mixed-citation>
</ref>
<ref id="bibr20-2045125319858901">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>La Rosa</surname><given-names>F</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Ratto</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>The gut-brain axis in Alzheimer’s disease and
omega-3. A critical overview of clinical trials</article-title>.
<source/>Nutrients
<year>2018</year>; <fpage>10</fpage>.</mixed-citation>
</ref>
<ref id="bibr21-2045125319858901">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hooijmans</surname><given-names>CR</given-names></name><name><surname>Pasker-de Jong</surname><given-names>PC</given-names></name><name><surname>de Vries</surname><given-names>RB</given-names></name><etal>et al</etal></person-group>
<article-title>The effects of long-term omega-3 fatty acid
supplementation on cognition and Alzheimer’s pathology in animal models of
Alzheimer’s disease: a systematic review and meta-analysis</article-title>.
<source/>J Alzheimers Dis
<year>2012</year>; <volume>28</volume>:
<fpage>191</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="pmid">22002791</pub-id></mixed-citation>
</ref>
<ref id="bibr22-2045125319858901">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simopoulos</surname><given-names>AP.</given-names></name></person-group>
<article-title>The importance of the omega-6/omega-3 fatty acid ratio in
cardiovascular disease and other chronic diseases</article-title>.
<source/>Exp Biol Med (Maywood)
<year>2008</year>; <volume>233</volume>:
<fpage>674</fpage>–<lpage>688</lpage>.<pub-id pub-id-type="pmid">18408140</pub-id></mixed-citation>
</ref>
<ref id="bibr23-2045125319858901">
<label>23</label>
<mixed-citation publication-type="web">
<collab>World Health Organization</collab>. <article-title>Population nutrient
intake goals for preventing diet-related chronic diseases</article-title>,
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/nutrition/topics/5_population_nutrient/en/index12.html">https://www.who.int/nutrition/topics/5_population_nutrient/en/index12.html</ext-link>
(<collab>accessed 15 January 2019</collab>).</mixed-citation>
</ref>
<ref id="bibr24-2045125319858901">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>The role of nutrients in protecting
mitochondrial function and neurotransmitter signaling: implications for the
treatment of depression, PTSD, and suicidal behaviors</article-title>.
<source/>Crit Rev Food Sci Nutr
<year>2016</year>; <volume>56</volume>:
<fpage>2560</fpage>–<lpage>2578</lpage>.<pub-id pub-id-type="pmid">25365455</pub-id></mixed-citation>
</ref>
<ref id="bibr25-2045125319858901">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cameron-Smith</surname><given-names>D</given-names></name><name><surname>Albert</surname><given-names>BB</given-names></name><name><surname>Cutfield</surname><given-names>WS.</given-names></name></person-group>
<article-title>Fishing for answers: is oxidation of fish oil supplements a
problem?</article-title>
<source/>J Nutr Sci
<year>2015</year>; <volume>4</volume>: <fpage>e36</fpage>.<pub-id pub-id-type="pmid">26688722</pub-id></mixed-citation>
</ref>
<ref id="bibr26-2045125319858901">
<label>26</label>
<mixed-citation publication-type="book">
<collab>NOFIMA</collab>. <source/>Rapport nr. 196: Lite oksiderte omega-3 oljer
og potensielle helsefordeler; <year>2010</year>
<publisher-name>Trondheim</publisher-name>,
<publisher-loc>Norway</publisher-loc>.</mixed-citation>
</ref>
<ref id="bibr27-2045125319858901">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sullivan Ritter</surname><given-names>JC</given-names></name><name><surname>Budge</surname><given-names>SM</given-names></name><name><surname>Jovica</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Oxidation rates of triacylglycerol and ethyl
ester fish oils</article-title>. <source/>J Am Oil Chem Soc Journal of the
American Oil Chemists’ Society
<year>2015</year>; <volume>92</volume>:
<fpage>561</fpage>–<lpage>569</lpage>.</mixed-citation>
</ref>
<ref id="bibr28-2045125319858901">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clayton</surname><given-names>PR</given-names></name><name><surname>Ladi</surname><given-names>S.</given-names></name></person-group>
<article-title>From alga to omega; have we reached peak (fish)
oil?</article-title>
<source/>J R Soc Med
<year>2015</year>; <volume>108</volume>:
<fpage>351</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">26359136</pub-id></mixed-citation>
</ref>
<ref id="bibr29-2045125319858901">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortega</surname><given-names>RM</given-names></name><name><surname>Rodriguez-Rodriguez</surname><given-names>E</given-names></name><name><surname>Lopez-Sobaler</surname><given-names>AM.</given-names></name></person-group>
<article-title>Effects of omega 3 fatty acids supplementation in behavior and
non-neurodegenerative neuropsychiatric disorders</article-title>. <source/>Br
J Nutr
<year>2012</year>; <volume>107</volume>(<issue>Suppl. 2</issue>):
<fpage>S261</fpage>–<lpage>S270</lpage>.<pub-id pub-id-type="pmid">22591900</pub-id></mixed-citation>
</ref>
<ref id="bibr30-2045125319858901">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bentsen</surname><given-names>H</given-names></name><name><surname>Osnes</surname><given-names>K</given-names></name><name><surname>Refsum</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>A randomized placebo-controlled trial of an
omega-3 fatty acid and vitamins E+C in schizophrenia</article-title>.
<source/>Transl Psychiatry
<year>2013</year>; <volume>3</volume>: <fpage>e335</fpage>.<pub-id pub-id-type="pmid">24346133</pub-id></mixed-citation>
</ref>
<ref id="bibr31-2045125319858901">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biesalski</surname><given-names>HK</given-names></name><name><surname>Erdman</surname><given-names>JW</given-names></name><name><surname>Hathcock</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Nutrient reference values for bioactives: new
approaches needed? A conference report</article-title>. <source/>Euro J
Nut
<year>2013</year>; <volume>52</volume>:
<fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="bibr32-2045125319858901">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS.</given-names></name></person-group>
<article-title>The Omega-6:Omega-3 ratio: a critical appraisal and possible
successor</article-title>. <source/>Prostaglandins Leukot Essent Fatty
Acids
<year>2018</year>; <volume>132</volume>:
<fpage>34</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">29599053</pub-id></mixed-citation>
</ref>
<ref id="bibr33-2045125319858901">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Schacky</surname><given-names>C</given-names></name></person-group>
<article-title>Omega-3 index and cardiovascular
health</article-title>. <source/>Nutrients
<year>2014</year>; <volume>6</volume>:
<fpage>799</fpage>–<lpage>814</lpage>.<pub-id pub-id-type="pmid">24566438</pub-id></mixed-citation>
</ref>
<ref id="bibr34-2045125319858901">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oseeva</surname><given-names>M</given-names></name><name><surname>Paluchova</surname><given-names>V</given-names></name><name><surname>Zacek</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 index in the Czech Republic: no
difference between urban and rural populations</article-title>. <source/>Chem
Phys Lipids
<year>2019</year>; <volume>220</volume>:
<fpage>23</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">30797755</pub-id></mixed-citation>
</ref>
<ref id="bibr35-2045125319858901">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berliner</surname><given-names>D</given-names></name><name><surname>Mattern</surname><given-names>S</given-names></name><name><surname>Wellige</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>The omega-3 index in patients with heart
failure: a prospective cohort study</article-title>. <source/>Prostaglandins
Leukot Essent Fatty Acids
<year>2019</year>; <volume>140</volume>:
<fpage>34</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">30553401</pub-id></mixed-citation>
</ref>
<ref id="bibr36-2045125319858901">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Morio</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 index levels and associated factors in a
middle-aged French population: the MONA LISA-NUT Study</article-title>.
<source/>Eur J Clin Nutr
<year>2015</year>; <volume>69</volume>:
<fpage>436</fpage>–<lpage>441</lpage>.<pub-id pub-id-type="pmid">25335443</pub-id></mixed-citation>
</ref>
<ref id="bibr37-2045125319858901">
<label>37</label>
<mixed-citation publication-type="web">
<collab>OmegaQuant Analytics, LLC</collab>, <ext-link ext-link-type="uri" xlink:href="https://omegaquant.com/about/">https://omegaquant.com/about/</ext-link> (<collab>accessed May 11
2019</collab>).</mixed-citation>
</ref>
<ref id="bibr38-2045125319858901">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fenton</surname><given-names>JI</given-names></name><name><surname>Gurzell</surname><given-names>EA</given-names></name><name><surname>Davidson</surname><given-names>EA</given-names></name><etal>et al</etal></person-group>
<article-title>Red blood cell PUFAs reflect the phospholipid
PUFA composition of major organs</article-title>. <source/>Prostaglandins
Leukot Essent Fatty Acids
<year>2016</year>; <volume>112</volume>:
<fpage>12</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">27637336</pub-id></mixed-citation>
</ref>
<ref id="bibr39-2045125319858901">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>M.</given-names></name></person-group>
<article-title>Polyunsaturated fatty acids in the developing human brain,
erythrocytes and plasma in peroxisomal disease: therapeutic
implications</article-title>. <source/>J Inherit Metab Dis
<year>1995</year>; <volume>18</volume>(<issue>Suppl. 1</issue>):
<fpage>61</fpage>–<lpage>75</lpage>.</mixed-citation>
</ref>
<ref id="bibr40-2045125319858901">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Letondor</surname><given-names>A</given-names></name><name><surname>Buaud</surname><given-names>B</given-names></name><name><surname>Vaysse</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Erythrocyte DHA level as a biomarker of DHA
status in specific brain regions of n-3 long-chain PUFA-supplemented aged
rats</article-title>. <source/>Br J Nutr
<year>2014</year>; <volume>112</volume>:
<fpage>1805</fpage>–<lpage>1818</lpage>.<pub-id pub-id-type="pmid">25331622</pub-id></mixed-citation>
</ref>
<ref id="bibr41-2045125319858901">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Christophe</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Fatty acid composition in major depression:
decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega
6/C20:5 omega 3 ratio in cholesteryl esters and
phospholipids</article-title>. <source/>J Affect Disord
<year>1996</year>; <volume>38</volume>:
<fpage>35</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">8735157</pub-id></mixed-citation>
</ref>
<ref id="bibr42-2045125319858901">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grosso</surname><given-names>G</given-names></name><name><surname>Micek</surname><given-names>A</given-names></name><name><surname>Marventano</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary n-3 PUFA, fish consumption and
depression: A systematic review and meta-analysis of observational
studies</article-title>. <source/>J Affect Disord
<year>2016</year>; <volume>205</volume>:
<fpage>269</fpage>–<lpage>281</lpage>.<pub-id pub-id-type="pmid">27544316</pub-id></mixed-citation>
</ref>
<ref id="bibr43-2045125319858901">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibbeln</surname><given-names>JR.</given-names></name></person-group>
<article-title>Fish consumption and major depression</article-title>.
<source/>Lancet
<year>1998</year>; <volume>351</volume>: <year>1213</year>.</mixed-citation>
</ref>
<ref id="bibr44-2045125319858901">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Cohen</surname><given-names>BE</given-names></name><etal>et al</etal></person-group>
<article-title>Association between omega-3 fatty acids and
depressive symptoms among patients with established coronary artery disease:
data from the Heart and Soul Study</article-title>. <source/>Psychother
Psychosom
<year>2009</year>; <volume>78</volume>:
<fpage>125</fpage>–<lpage>127</lpage>.<pub-id pub-id-type="pmid">19223688</pub-id></mixed-citation>
</ref>
<ref id="bibr45-2045125319858901">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>AA</given-names></name><name><surname>Menon</surname><given-names>RA</given-names></name><name><surname>Reid</surname><given-names>KJ</given-names></name><etal>et al</etal></person-group>
<article-title>Acute coronary syndrome patients with depression
have low blood cell membrane omega-3 fatty acid levels</article-title>.
<source/>Psychosom Med
<year>2008</year>; <volume>70</volume>:
<fpage>856</fpage>–<lpage>862</lpage>.<pub-id pub-id-type="pmid">18842751</pub-id></mixed-citation>
</ref>
<ref id="bibr46-2045125319858901">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reeves</surname><given-names>JL</given-names></name><name><surname>Otahal</surname><given-names>P</given-names></name><name><surname>Magnussen</surname><given-names>CG</given-names></name><etal>et al</etal></person-group>
<article-title>DHA mediates the protective effect of fish
consumption on new episodes of depression among women</article-title>.
<source/>Br J Nutr
<year>2017</year>; <volume>118</volume>:
<fpage>743</fpage>–<lpage>749</lpage>.<pub-id pub-id-type="pmid">29185935</pub-id></mixed-citation>
</ref>
<ref id="bibr47-2045125319858901">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baghai</surname><given-names>TC</given-names></name><name><surname>Varallo-Bedarida</surname><given-names>G</given-names></name><name><surname>Born</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Major depressive disorder is associated with
cardiovascular risk factors and low Omega-3 Index</article-title>. <source/>J
Clin Psychiatry
<year>2011</year>; <volume>72</volume>:
<fpage>1242</fpage>–<lpage>1247</lpage>.<pub-id pub-id-type="pmid">21208589</pub-id></mixed-citation>
</ref>
<ref id="bibr48-2045125319858901">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanchez-Villegas</surname><given-names>A</given-names></name><name><surname>Alvarez-Perez</surname><given-names>J</given-names></name><name><surname>Toledo</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Seafood Consumption, Omega-3 Fatty Acids Intake,
and Life-Time Prevalence of Depression in the PREDIMED-Plus
Trial</article-title>. <source/>Nutrients
<year>2018</year>; <fpage>10</fpage>.</mixed-citation>
</ref>
<ref id="bibr49-2045125319858901">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pottala</surname><given-names>JV</given-names></name><name><surname>Talley</surname><given-names>JA</given-names></name><name><surname>Churchill</surname><given-names>SW</given-names></name><etal>et al</etal></person-group>
<article-title>Red blood cell fatty acids are associated with
depression in a case-control study of adolescents</article-title>.
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2012</year>; <volume>86</volume>:
<fpage>161</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">22464051</pub-id></mixed-citation>
</ref>
<ref id="bibr50-2045125319858901">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swenne</surname><given-names>I</given-names></name><name><surname>Rosling</surname><given-names>A</given-names></name><name><surname>Tengblad</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 polyunsaturated essential fatty acids
are associated with depression in adolescents with eating disorders and
weight loss</article-title>. <source/>Acta Paediatr
<year>2011</year>; <volume>100</volume>:
<fpage>1610</fpage>–<lpage>1615</lpage>.<pub-id pub-id-type="pmid">21732977</pub-id></mixed-citation>
</ref>
<ref id="bibr51-2045125319858901">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Conklin</surname><given-names>SM</given-names></name><name><surname>Manuck</surname><given-names>SB</given-names></name><name><surname>Yao</surname><given-names>JK</given-names></name><etal>et al</etal></person-group>
<article-title>High omega-6 and low omega-3 fatty acids are
associated with depressive symptoms and neuroticism</article-title>.
<source/>Psychosom Med
<year>2007</year>; <volume>69</volume>:
<fpage>932</fpage>–<lpage>934</lpage>.<pub-id pub-id-type="pmid">17991818</pub-id></mixed-citation>
</ref>
<ref id="bibr52-2045125319858901">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>PY</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Su</surname><given-names>KP.</given-names></name></person-group>
<article-title>A meta-analytic review of polyunsaturated fatty acid compositions
in patients with depression</article-title>. <source/>Biol
Psychiatry
<year>2010</year>; <volume>68</volume>:
<fpage>140</fpage>–<lpage>147</lpage>.<pub-id pub-id-type="pmid">20452573</pub-id></mixed-citation>
</ref>
<ref id="bibr53-2045125319858901">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edwards</surname><given-names>R</given-names></name><name><surname>Peet</surname><given-names>M</given-names></name><name><surname>Shay</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 polyunsaturated fatty acid levels in the
diet and in red blood cell membranes of depressed patients</article-title>.
<source/>J Affect Disord
<year>1998</year>; <volume>48</volume>:
<fpage>149</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">9543204</pub-id></mixed-citation>
</ref>
<ref id="bibr54-2045125319858901">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gow</surname><given-names>RV</given-names></name><name><surname>Hibbeln</surname><given-names>JR.</given-names></name></person-group>
<article-title>Omega-3 fatty acid and nutrient deficits in adverse
neurodevelopment and childhood behaviors</article-title>. <source/>Child
Adolesc Psychiatr Clin N Am
<year>2014</year>; <volume>23</volume>:
<fpage>555</fpage>–<lpage>590</lpage>.<pub-id pub-id-type="pmid">24975625</pub-id></mixed-citation>
</ref>
<ref id="bibr55-2045125319858901">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibbeln</surname><given-names>JR</given-names></name><name><surname>Gow</surname><given-names>RV.</given-names></name></person-group>
<article-title>The potential for military diets to reduce depression, suicide,
and impulsive aggression: a review of current evidence for omega-3 and
omega-6 fatty acids</article-title>. <source/>Mil Med
<year>2014</year>; <volume>179</volume>:
<fpage>117</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">25373095</pub-id></mixed-citation>
</ref>
<ref id="bibr56-2045125319858901">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Baek</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Erythrocyte n-3 polyunsaturated fatty acid and
seafood intake decrease the risk of depression: case-control study in
Korea</article-title>. <source/>Ann Nutr Metab
<year>2012</year>; <volume>61</volume>:
<fpage>25</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">22776859</pub-id></mixed-citation>
</ref>
<ref id="bibr57-2045125319858901">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colin</surname><given-names>A</given-names></name><name><surname>Reggers</surname><given-names>J</given-names></name><name><surname>Castronovo</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Lipids, depression and suicide</article-title>.
<source/>Encephale
<year>2003</year>; <volume>29</volume>:
<fpage>49</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">12640327</pub-id></mixed-citation>
</ref>
<ref id="bibr58-2045125319858901">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peet</surname><given-names>M</given-names></name><name><surname>Horrobin</surname><given-names>DF.</given-names></name></person-group>
<article-title>A dose-ranging study of the effects of ethyl-eicosapentaenoate in
patients with ongoing depression despite apparently adequate treatment with
standard drugs</article-title>. <source/>Arch Gen Psychiatry
<year>2002</year>; <volume>59</volume>:
<fpage>913</fpage>–<lpage>919</lpage>.<pub-id pub-id-type="pmid">12365878</pub-id></mixed-citation>
</ref>
<ref id="bibr59-2045125319858901">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Rubin</surname><given-names>EH</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 augmentation of sertraline in treatment
of depression in patients with coronary heart disease: a randomized
controlled trial</article-title>. <source/>JAMA
<year>2009</year>; <volume>302</volume>:
<fpage>1651</fpage>–<lpage>1657</lpage>.<pub-id pub-id-type="pmid">19843899</pub-id></mixed-citation>
</ref>
<ref id="bibr60-2045125319858901">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sublette</surname><given-names>ME</given-names></name><name><surname>Ellis</surname><given-names>SP</given-names></name><name><surname>Geant</surname><given-names>AL</given-names></name><etal>et al</etal></person-group>
<article-title>Meta-analysis of the effects of eicosapentaenoic
acid (EPA) in clinical trials in depression</article-title>. <source/>J Clin
Psychiatry
<year>2011</year>; <volume>72</volume>:
<fpage>1577</fpage>–<lpage>1584</lpage>.<pub-id pub-id-type="pmid">21939614</pub-id></mixed-citation>
</ref>
<ref id="bibr61-2045125319858901">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grosso</surname><given-names>G</given-names></name><name><surname>Pajak</surname><given-names>A</given-names></name><name><surname>Marventano</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Role of omega-3 fatty acids in the treatment of
depressive disorders: a comprehensive meta-analysis of randomized clinical
trials</article-title>. <source/>PLoS One
<year>2014</year>; <volume>9</volume>: <fpage>e96905</fpage>.<pub-id pub-id-type="pmid">24805797</pub-id></mixed-citation>
</ref>
<ref id="bibr62-2045125319858901">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Mischoulon</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Adjunctive Nutraceuticals for Depression: A
Systematic Review and Meta-Analyses</article-title>. <source/>Am J
Psychiatry
<year>2016</year>; <volume>173</volume>:
<fpage>575</fpage>–<lpage>587</lpage>.<pub-id pub-id-type="pmid">27113121</pub-id></mixed-citation>
</ref>
<ref id="bibr63-2045125319858901">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Je</surname><given-names>Y.</given-names></name></person-group>
<article-title>Fish consumption and risk of depression: Epidemiological evidence
from prospective studies</article-title>. <source/>Asia Pac
Psychiatry
<year>2018</year>; <volume>10</volume>: <fpage>e12335</fpage>.<pub-id pub-id-type="pmid">30238628</pub-id></mixed-citation>
</ref>
<ref id="bibr64-2045125319858901">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martins</surname><given-names>JG.</given-names></name></person-group>
<article-title>EPA but not DHA appears to be responsible for the efficacy of
omega-3 long chain polyunsaturated fatty acid supplementation in depression:
evidence from a meta-analysis of randomized controlled
trials</article-title>. <source/>J Am Coll Nutr
<year>2009</year>; <volume>28</volume>:
<fpage>525</fpage>–<lpage>542</lpage>.<pub-id pub-id-type="pmid">20439549</pub-id></mixed-citation>
</ref>
<ref id="bibr65-2045125319858901">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su</surname><given-names>KP</given-names></name><name><surname>Yang</surname><given-names>HT</given-names></name><name><surname>Chang</surname><given-names>JP</given-names></name><etal>et al</etal></person-group>
<article-title>Eicosapentaenoic and docosahexaenoic acids have
different effects on peripheral phospholipase A2 gene expressions in acute
depressed patients</article-title>. <source/>Prog Neuropsychopharmacol Biol
Psychiatry
<year>2018</year>; <volume>80</volume>:
<fpage>227</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">28648567</pub-id></mixed-citation>
</ref>
<ref id="bibr66-2045125319858901">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gananca</surname><given-names>L</given-names></name><name><surname>Galfalvy</surname><given-names>HC</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><etal>et al</etal></person-group>
<article-title>Lipid correlates of antidepressant response to
omega-3 polyunsaturated fatty acid supplementation: A pilot
study</article-title>. <source/>Prostaglandins Leukot Essent Fatty
Acids
<year>2017</year>; <volume>119</volume>:
<fpage>38</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">28410668</pub-id></mixed-citation>
</ref>
<ref id="bibr67-2045125319858901">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noaghiul</surname><given-names>S</given-names></name><name><surname>Hibbeln</surname><given-names>JR.</given-names></name></person-group>
<article-title>Cross-national comparisons of seafood consumption and rates of
bipolar disorders</article-title>. <source/>Am J Psychiatry
<year>2003</year>; <volume>160</volume>:
<fpage>2222</fpage>–<lpage>2227</lpage>.<pub-id pub-id-type="pmid">14638594</pub-id></mixed-citation>
</ref>
<ref id="bibr68-2045125319858901">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tiemeier</surname><given-names>H</given-names></name><name><surname>van Tuijl</surname><given-names>HR</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Plasma fatty acid composition and depression are
associated in the elderly: the Rotterdam Study</article-title>. <source/>Am J
Clin Nutr
<year>2003</year>; <volume>78</volume>:
<fpage>40</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">12816769</pub-id></mixed-citation>
</ref>
<ref id="bibr69-2045125319858901">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Mischoulon</surname><given-names>D</given-names></name><name><surname>Schweitzer</surname><given-names>I.</given-names></name></person-group>
<article-title>Omega-3 for bipolar disorder: meta-analyses of use in mania and
bipolar depression</article-title>. <source/>J Clin Psychiatry
<year>2012</year>; <volume>73</volume>:
<fpage>81</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">21903025</pub-id></mixed-citation>
</ref>
<ref id="bibr70-2045125319858901">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoll</surname><given-names>AL</given-names></name><name><surname>Severus</surname><given-names>WE</given-names></name><name><surname>Freeman</surname><given-names>MP</given-names></name><etal>et al</etal></person-group>
<article-title>Omega 3 fatty acids in bipolar disorder: a
preliminary double-blind, placebo-controlled trial</article-title>.
<source/>Arch Gen Psychiatry
<year>1999</year>; <volume>56</volume>:
<fpage>407</fpage>–<lpage>412</lpage>.<pub-id pub-id-type="pmid">10232294</pub-id></mixed-citation>
</ref>
<ref id="bibr71-2045125319858901">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nemets</surname><given-names>H</given-names></name><name><surname>Nemets</surname><given-names>B</given-names></name><name><surname>Apter</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 treatment of childhood depression: a
controlled, double-blind pilot study</article-title>. <source/>Am J
Psychiatry
<year>2006</year>; <volume>163</volume>:
<fpage>1098</fpage>–<lpage>1100</lpage>.<pub-id pub-id-type="pmid">16741212</pub-id></mixed-citation>
</ref>
<ref id="bibr72-2045125319858901">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>ME</given-names></name><name><surname>Smesny</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-6 to omega-3 polyunsaturated fatty acid
ratio and subsequent mood disorders in young people with at-risk mental
states: a 7-year longitudinal study</article-title>. <source/>Transl
Psychiatry
<year>2017</year>; <volume>7</volume>: <fpage>e1220</fpage>.<pub-id pub-id-type="pmid">28850110</pub-id></mixed-citation>
</ref>
<ref id="bibr73-2045125319858901">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Czysz</surname><given-names>AH</given-names></name><name><surname>Rasenick</surname><given-names>MM.</given-names></name></person-group>
<article-title>G-protein signaling, lipid rafts and the possible sites of action
for the antidepressant effects of n-3 polyunsaturated fatty
acids</article-title>. <source/>CNS Neurol Disord Drug Targets
<year>2013</year>; <volume>12</volume>:
<fpage>466</fpage>–<lpage>473</lpage>.<pub-id pub-id-type="pmid">23574156</pub-id></mixed-citation>
</ref>
<ref id="bibr74-2045125319858901">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su</surname><given-names>KP</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Peng</surname><given-names>CY</given-names></name><etal>et al</etal></person-group>
<article-title>Phospholipase A2 and cyclooxygenase 2 genes
influence the risk of interferon-alpha-induced depression by regulating
polyunsaturated fatty acids levels</article-title>. <source/>Biol
Psychiatry
<year>2010</year>; <volume>67</volume>:
<fpage>550</fpage>–<lpage>557</lpage>.<pub-id pub-id-type="pmid">20034614</pub-id></mixed-citation>
</ref>
<ref id="bibr75-2045125319858901">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horrobin</surname><given-names>DF.</given-names></name></person-group>
<article-title>The membrane phospholipid hypothesis as a biochemical basis for
the neurodevelopmental concept of schizophrenia</article-title>.
<source/>Schizophr Res
<year>1998</year>; <volume>30</volume>:
<fpage>193</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">9589514</pub-id></mixed-citation>
</ref>
<ref id="bibr76-2045125319858901">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horrobin</surname><given-names>DF</given-names></name><name><surname>Glen</surname><given-names>AI</given-names></name><name><surname>Vaddadi</surname><given-names>K.</given-names></name></person-group>
<article-title>The membrane hypothesis of schizophrenia</article-title>.
<source/>Schizophr Res
<year>1994</year>; <volume>13</volume>:
<fpage>195</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">7841132</pub-id></mixed-citation>
</ref>
<ref id="bibr77-2045125319858901">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peet</surname><given-names>M</given-names></name><name><surname>Laugharne</surname><given-names>JD</given-names></name><name><surname>Mellor</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Essential fatty acid deficiency in erythrocyte
membranes from chronic schizophrenic patients, and the clinical effects of
dietary supplementation</article-title>. <source/>Prostaglandins Leukot
Essent Fatty Acids
<year>1996</year>; <volume>55</volume>:
<fpage>71</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">8888126</pub-id></mixed-citation>
</ref>
<ref id="bibr78-2045125319858901">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peet</surname><given-names>M</given-names></name><name><surname>Brind</surname><given-names>J</given-names></name><name><surname>Ramchand</surname><given-names>CN</given-names></name><etal>et al</etal></person-group>
<article-title>Two double-blind placebo-controlled pilot
studies of eicosapentaenoic acid in the treatment of
schizophrenia</article-title>. <source/>Schizophr Res
<year>2001</year>; <volume>49</volume>:
<fpage>243</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">11356585</pub-id></mixed-citation>
</ref>
<ref id="bibr79-2045125319858901">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emsley</surname><given-names>R</given-names></name><name><surname>Myburgh</surname><given-names>C</given-names></name><name><surname>Oosthuizen</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Randomized, placebo-controlled study of
ethyl-eicosapentaenoic acid as supplemental treatment in
schizophrenia</article-title>. <source/>Am J Psychiatry
<year>2002</year>; <volume>159</volume>:
<fpage>1596</fpage>–<lpage>1598</lpage>.<pub-id pub-id-type="pmid">12202284</pub-id></mixed-citation>
</ref>
<ref id="bibr80-2045125319858901">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jamilian</surname><given-names>H</given-names></name><name><surname>Solhi</surname><given-names>H</given-names></name><name><surname>Jamilian</surname><given-names>M.</given-names></name></person-group>
<article-title>Randomized, placebo-controlled clinical trial of omega-3 as
supplemental treatment in schizophrenia</article-title>. <source/>Glob J
Health Sci
<year>2014</year>; <volume>6</volume>:
<fpage>103</fpage>–<lpage>108</lpage>.<pub-id pub-id-type="pmid">25363186</pub-id></mixed-citation>
</ref>
<ref id="bibr81-2045125319858901">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>GE</given-names></name><name><surname>Proffitt</surname><given-names>TM</given-names></name><name><surname>McConchie</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Ethyl-eicosapentaenoic acid in first-episode
psychosis: a randomized, placebo-controlled trial</article-title>. <source/>J
Clin Psychiatry
<year>2007</year>; <volume>68</volume>:
<fpage>1867</fpage>–<lpage>1875</lpage>.<pub-id pub-id-type="pmid">18162017</pub-id></mixed-citation>
</ref>
<ref id="bibr82-2045125319858901">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peet</surname><given-names>M</given-names></name><name><surname>Horrobin</surname><given-names>DF</given-names></name><name><surname>Group</surname><given-names>EEMS</given-names></name></person-group>
<article-title>A dose-ranging exploratory study of the effects
of ethyl-eicosapentaenoate in patients with persistent schizophrenic
symptoms</article-title>. <source/>J Psychiatr Res
<year>2002</year>; <volume>36</volume>:
<fpage>7</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">11755456</pub-id></mixed-citation>
</ref>
<ref id="bibr83-2045125319858901">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fenton</surname><given-names>WS</given-names></name><name><surname>Dickerson</surname><given-names>F</given-names></name><name><surname>Boronow</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>A placebo-controlled trial of omega-3 fatty acid
(ethyl eicosapentaenoic acid) supplementation for residual symptoms and
cognitive impairment in schizophrenia</article-title>. <source/>Am J
Psychiatry
<year>2001</year>; <volume>158</volume>:
<fpage>2071</fpage>–<lpage>2074</lpage>.<pub-id pub-id-type="pmid">11729030</pub-id></mixed-citation>
</ref>
<ref id="bibr84-2045125319858901">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawelczyk</surname><given-names>T</given-names></name><name><surname>Grancow-Grabka</surname><given-names>M</given-names></name><name><surname>Kotlicka-Antczak</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>A randomized controlled study of the efficacy of
six-month supplementation with concentrated fish oil rich in omega-3
polyunsaturated fatty acids in first episode schizophrenia</article-title>.
<source/>J Psychiatr Res
<year>2016</year>; <volume>73</volume>:
<fpage>34</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">26679763</pub-id></mixed-citation>
</ref>
<ref id="bibr85-2045125319858901">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taha</surname><given-names>AY</given-names></name><name><surname>Cheon</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Altered fatty acid concentrations in prefrontal
cortex of schizophrenic patients</article-title>. <source/>J Psychiatr
Res
<year>2013</year>; <volume>47</volume>:
<fpage>636</fpage>–<lpage>643</lpage>.<pub-id pub-id-type="pmid">23428160</pub-id></mixed-citation>
</ref>
<ref id="bibr86-2045125319858901">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>BMM</given-names></name><name><surname>Chaves Filho</surname><given-names>AJM</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>N-3 polyunsaturated fatty acids and clozapine
abrogates poly I: C-induced immune alterations in primary hippocampal
neurons</article-title>. <source/>Prog Neuropsychopharmacol Biol
Psychiatry
<year>2019</year>; <volume>90</volume>:
<fpage>186</fpage>–<lpage>196</lpage>.<pub-id pub-id-type="pmid">30508574</pub-id></mixed-citation>
</ref>
<ref id="bibr87-2045125319858901">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawelczyk</surname><given-names>T</given-names></name><name><surname>Grancow-Grabka</surname><given-names>M</given-names></name><name><surname>Trafalska</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Oxidative stress reduction related to the
efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia:
Secondary outcome analysis of the OFFER randomized trial</article-title>.
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2017</year>; <volume>121</volume>:
<fpage>7</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">28651701</pub-id></mixed-citation>
</ref>
<ref id="bibr88-2045125319858901">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>GE</given-names></name><name><surname>Wood</surname><given-names>SJ</given-names></name><name><surname>Wellard</surname><given-names>RM</given-names></name><etal>et al</etal></person-group>
<article-title>Ethyl-eicosapentaenoic acid in first-episode
psychosis. A 1H-MRS study</article-title>.
<source/>Neuropsychopharmacology
<year>2008</year>; <volume>33</volume>:
<fpage>2467</fpage>–<lpage>2473</lpage>.<pub-id pub-id-type="pmid">18199999</pub-id></mixed-citation>
</ref>
<ref id="bibr89-2045125319858901">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tesei</surname><given-names>A</given-names></name><name><surname>Crippa</surname><given-names>A</given-names></name><name><surname>Ceccarelli</surname><given-names>SB</given-names></name><etal>et al</etal></person-group>
<article-title>The potential relevance of docosahexaenoic acid
and eicosapentaenoic acid to the etiopathogenesis of childhood
neuropsychiatric disorders</article-title>. <source/>Eur Child Adolesc
Psychiatry
<year>2017</year>; <volume>26</volume>:
<fpage>1011</fpage>–<lpage>1030</lpage>.<pub-id pub-id-type="pmid">27988864</pub-id></mixed-citation>
</ref>
<ref id="bibr90-2045125319858901">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bondi</surname><given-names>CO</given-names></name><name><surname>Taha</surname><given-names>AY</given-names></name><name><surname>Tock</surname><given-names>JL</given-names></name><etal>et al</etal></person-group>
<article-title>Adolescent behavior and dopamine availability
are uniquely sensitive to dietary omega-3 fatty acid
deficiency</article-title>. <source/>Biol Psychiatry
<year>2014</year>; <volume>75</volume>:
<fpage>38</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">23890734</pub-id></mixed-citation>
</ref>
<ref id="bibr91-2045125319858901">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibbeln</surname><given-names>JR</given-names></name><name><surname>Davis</surname><given-names>JM</given-names></name><name><surname>Steer</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Maternal seafood consumption in pregnancy and
neurodevelopmental outcomes in childhood (ALSPAC study): an observational
cohort study</article-title>. <source/>Lancet
<year>2007</year>; <volume>369</volume>:
<fpage>578</fpage>–<lpage>585</lpage>.<pub-id pub-id-type="pmid">17307104</pub-id></mixed-citation>
</ref>
<ref id="bibr92-2045125319858901">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schuchardt</surname><given-names>JP</given-names></name><name><surname>Huss</surname><given-names>M</given-names></name><name><surname>Stauss-Grabo</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Significance of long-chain polyunsaturated fatty
acids (PUFAs) for the development and behaviour of children</article-title>.
<source/>Eur J Pediatr
<year>2010</year>; <volume>169</volume>:
<fpage>149</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">19672626</pub-id></mixed-citation>
</ref>
<ref id="bibr93-2045125319858901">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>P</given-names></name><name><surname>Burton</surname><given-names>JR</given-names></name><name><surname>Sewell</surname><given-names>RP</given-names></name><etal>et al</etal></person-group>
<article-title>Low blood long chain omega-3 fatty acids in UK
children are associated with poor cognitive performance and behavior: a
cross-sectional analysis from the DOLAB study</article-title>. <source/>PLoS
One
<year>2013</year>; <volume>8</volume>: <fpage>e66697</fpage>.<pub-id pub-id-type="pmid">23826114</pub-id></mixed-citation>
</ref>
<ref id="bibr94-2045125319858901">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawkey</surname><given-names>E</given-names></name><name><surname>Nigg</surname><given-names>JT.</given-names></name></person-group>
<article-title>Omega-3 fatty acid and ADHD: blood level analysis and
meta-analytic extension of supplementation trials</article-title>.
<source/>Clin Psychol Rev
<year>2014</year>; <volume>34</volume>:
<fpage>496</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">25181335</pub-id></mixed-citation>
</ref>
<ref id="bibr95-2045125319858901">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Widenhorn-Muller</surname><given-names>K</given-names></name><name><surname>Schwanda</surname><given-names>S</given-names></name><name><surname>Scholz</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of supplementation with long-chain
omega-3 polyunsaturated fatty acids on behavior and cognition in children
with attention deficit/hyperactivity disorder (ADHD): a randomized
placebo-controlled intervention trial</article-title>.
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2014</year>; <volume>91</volume>:
<fpage>49</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">24958525</pub-id></mixed-citation>
</ref>
<ref id="bibr96-2045125319858901">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parletta</surname><given-names>N</given-names></name><name><surname>Niyonsenga</surname><given-names>T</given-names></name><name><surname>Duff</surname><given-names>J.</given-names></name></person-group>
<article-title>Omega-3 and omega-6 polyunsaturated fatty acid levels and
correlations with symptoms in children with attention deficit hyperactivity
disorder, autistic spectrum disorder and typically developing
controls</article-title>. <source/>PLoS One
<year>2016</year>; <volume>11</volume>:
<fpage>e0156432</fpage>.<pub-id pub-id-type="pmid">27232999</pub-id></mixed-citation>
</ref>
<ref id="bibr97-2045125319858901">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Long</surname><given-names>SJ</given-names></name><name><surname>Benton</surname><given-names>D.</given-names></name></person-group>
<article-title>A double-blind trial of the effect of docosahexaenoic acid and
vitamin and mineral supplementation on aggression, impulsivity, and
stress</article-title>. <source/>Hum Psychopharmacol
<year>2013</year>; <volume>28</volume>:
<fpage>238</fpage>–<lpage>247</lpage>.<pub-id pub-id-type="pmid">23625531</pub-id></mixed-citation>
</ref>
<ref id="bibr98-2045125319858901">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raine</surname><given-names>A</given-names></name><name><surname>Portnoy</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Reduction in behavior problems with omega-3
supplementation in children aged 8–16 years: a randomized, double-blind,
placebo-controlled, stratified, parallel-group trial</article-title>.
<source/>J Child Psychol Psychiatry
<year>2015</year>; <volume>56</volume>:
<fpage>509</fpage>–<lpage>520</lpage>.<pub-id pub-id-type="pmid">25146492</pub-id></mixed-citation>
</ref>
<ref id="bibr99-2045125319858901">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Checa-Ros</surname><given-names>A</given-names></name><name><surname>Haro-Garcia</surname><given-names>A</given-names></name><name><surname>Seiquer</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>Early monitoring of fatty acid profile in
children with attention deficit and/or hyperactivity disorder under
treatment with omega-3 polyunsaturated fatty acids</article-title>.
<source/>Minerva Pediatr. Epub ahead of print 7 November 2018. DOI:
<pub-id pub-id-type="doi">10.23736/S0026-4946.18.04975-7</pub-id>.</mixed-citation>
</ref>
<ref id="bibr100-2045125319858901">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gillies</surname><given-names>D</given-names></name><name><surname>Sinn</surname><given-names>J</given-names></name><name><surname>Lad</surname><given-names>SS</given-names></name><etal>et al</etal></person-group>
<article-title>Polyunsaturated fatty acids (PUFA) for attention
deficit hyperactivity disorder (ADHD) in children and
adolescents</article-title>. <source/>Cochrane Database Syst Rev
<year>2012</year>: CD007986.</mixed-citation>
</ref>
<ref id="bibr101-2045125319858901">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rangel-Huerta</surname><given-names>OD</given-names></name><name><surname>Gil</surname><given-names>A.</given-names></name></person-group>
<article-title>Effect of omega-3 fatty acids on cognition: an updated systematic
review of randomized clinical trials</article-title>. <source/>Nutr
Rev
<year>2018</year>; <volume>76</volume>:
<fpage>1</fpage>–<lpage>20</lpage>.</mixed-citation>
</ref>
<ref id="bibr102-2045125319858901">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bloch</surname><given-names>MH</given-names></name><name><surname>Qawasmi</surname><given-names>A.</given-names></name></person-group>
<article-title>Omega-3 fatty acid supplementation for the treatment of children
with attention-deficit/hyperactivity disorder symptomatology: systematic
review and meta-analysis</article-title>. <source/>J Am Acad Child Adolesc
Psychiatry
<year>2011</year>; <volume>50</volume>:
<fpage>991</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">21961774</pub-id></mixed-citation>
</ref>
<ref id="bibr103-2045125319858901">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>JP</given-names></name><name><surname>Su</surname><given-names>KP</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 polyunsaturated fatty acids in youths
with attention deficit hyperactivity disorder: a systematic review and
meta-analysis of clinical trials and biological studies</article-title>.
<source/>Neuropsychopharmacology
<year>2018</year>; <volume>43</volume>:
<fpage>534</fpage>–<lpage>545</lpage>.<pub-id pub-id-type="pmid">28741625</pub-id></mixed-citation>
</ref>
<ref id="bibr104-2045125319858901">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdullah</surname><given-names>M</given-names></name><name><surname>Jowett</surname><given-names>B</given-names></name><name><surname>Whittaker</surname><given-names>PJ</given-names></name><etal>et al</etal></person-group>
<article-title>The effectiveness of omega-3 supplementation in
reducing ADHD associated symptoms in children as measured by the Conners’
rating scales: a systematic review of randomized controlled
trials</article-title>. <source/>J Psychiatr Res
<year>2018</year>; <volume>110</volume>:
<fpage>64</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">30594823</pub-id></mixed-citation>
</ref>
<ref id="bibr105-2045125319858901">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Artukoglu</surname><given-names>BB</given-names></name><name><surname>Bloch</surname><given-names>MH.</given-names></name></person-group>
<article-title>Editorial: can omega-3 fatty acids improve executive functioning?
Will this reduce ADHD and depression?</article-title>
<source/>J Child Psychol Psychiatry
<year>2018</year>; <volume>59</volume>:
<fpage>615</fpage>–<lpage>617</lpage>.<pub-id pub-id-type="pmid">29808491</pub-id></mixed-citation>
</ref>
<ref id="bibr106-2045125319858901">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramalho</surname><given-names>R</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Vicente</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Docosahexaenoic acid supplementation for
children with attention deficit hyperactivity disorder: a comprehensive
review of the evidence</article-title>. <source/>Clin Nutr ESPEN
<year>2018</year>; <volume>25</volume>:
<fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">29779801</pub-id></mixed-citation>
</ref>
<ref id="bibr107-2045125319858901">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konigs</surname><given-names>A</given-names></name><name><surname>Kiliaan</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Critical appraisal of omega-3 fatty acids in
attention-deficit/hyperactivity disorder treatment</article-title>.
<source/>Neuropsychiatr Dis Treat
<year>2016</year>; <volume>12</volume>:
<fpage>1869</fpage>–<lpage>1882</lpage>.<pub-id pub-id-type="pmid">27555775</pub-id></mixed-citation>
</ref>
<ref id="bibr108-2045125319858901">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>LL</given-names></name><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Horrocks</surname><given-names>LA</given-names></name><etal>et al</etal></person-group>
<article-title>Quantitative association between altered plasma
esterified omega-6 fatty acid proportions and psychological
stress</article-title>. <source/>Prostaglandins Leukot Essent Fatty
Acids
<year>1992</year>; <volume>47</volume>:
<fpage>165</fpage>–<lpage>170</lpage>.<pub-id pub-id-type="pmid">1461929</pub-id></mixed-citation>
</ref>
<ref id="bibr109-2045125319858901">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alden</surname><given-names>PB</given-names></name><name><surname>Svingen</surname><given-names>BA</given-names></name><name><surname>Johnson</surname><given-names>SB</given-names></name><etal>et al</etal></person-group>
<article-title>Partial correction by exogenous lipid of
abnormal patterns of polyunsaturated fatty acids in plasma phospholipids of
stressed and septic surgical patients</article-title>.
<source/>Surgery
<year>1986</year>; <volume>100</volume>:
<fpage>671</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">3094185</pub-id></mixed-citation>
</ref>
<ref id="bibr110-2045125319858901">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vries</surname><given-names>GJ</given-names></name><name><surname>Mocking</surname><given-names>R</given-names></name><name><surname>Lok</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Fatty acid concentrations in patients with
posttraumatic stress disorder compared to healthy controls</article-title>.
<source/>J Affect Disord
<year>2016</year>; <volume>205</volume>:
<fpage>351</fpage>–<lpage>359</lpage>.<pub-id pub-id-type="pmid">27567082</pub-id></mixed-citation>
</ref>
<ref id="bibr111-2045125319858901">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalinic</surname><given-names>D</given-names></name><name><surname>Borovac Stefanovic</surname><given-names>L</given-names></name><name><surname>Jeroncic</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Eicosapentaenoic acid in serum lipids could be
inversely correlated with severity of clinical symptomatology in Croatian
war veterans with posttraumatic stress disorder</article-title>.
<source/>Croat Med J
<year>2014</year>; <volume>55</volume>:
<fpage>27</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">24577824</pub-id></mixed-citation>
</ref>
<ref id="bibr112-2045125319858901">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Hamazaki</surname><given-names>K.</given-names></name></person-group>
<article-title>Serum levels of polyunsaturated fatty acids and the risk of
posttraumatic stress disorder</article-title>. <source/>Psychother
Psychosom
<year>2013</year>; <volume>82</volume>:
<fpage>408</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">24080850</pub-id></mixed-citation>
</ref>
<ref id="bibr113-2045125319858901">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Yonemoto</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acids for secondary prevention of
posttraumatic stress disorder after accidental injury: an open-label pilot
study</article-title>. <source/>J Clin Psychopharmacol
<year>2010</year>; <volume>30</volume>:
<fpage>217</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">20520307</pub-id></mixed-citation>
</ref>
<ref id="bibr114-2045125319858901">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Hamazaki</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Docosahexaenoic acid for selective prevention of
posttraumatic stress disorder among severely injured patients: a randomized,
placebo-controlled trial</article-title>. <source/>J Clin Psychiatry
<year>2015</year>; <volume>76</volume>:
<fpage>e1015</fpage>–<lpage>1022</lpage>.<pub-id pub-id-type="pmid">26335087</pub-id></mixed-citation>
</ref>
<ref id="bibr115-2045125319858901">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of omega-3 polyunsaturated fatty acids
on psychophysiological symptoms of post-traumatic stress disorder in
accident survivors: a randomized, double-blind, placebo-controlled
trial</article-title>. <source/>J Affect Disord
<year>2017</year>; <volume>224</volume>:
<fpage>27</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">27287561</pub-id></mixed-citation>
</ref>
<ref id="bibr116-2045125319858901">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Koido</surname><given-names>Y</given-names></name><name><surname>Nakaya</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Fish oil for attenuating posttraumatic stress
symptoms among rescue workers after the great east Japan earthquake: a
randomized controlled trial</article-title>. <source/>Psychother
Psychosom
<year>2012</year>; <volume>81</volume>:
<fpage>315</fpage>–<lpage>317</lpage>.<pub-id pub-id-type="pmid">22854784</pub-id></mixed-citation>
</ref>
<ref id="bibr117-2045125319858901">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Passos</surname><given-names>IC</given-names></name><name><surname>Vasconcelos-Moreno</surname><given-names>MP</given-names></name><name><surname>Costa</surname><given-names>LG</given-names></name><etal>et al</etal></person-group>
<article-title>Inflammatory markers in post-traumatic stress
disorder: a systematic review, meta-analysis, and
meta-regression</article-title>. <source/>Lancet Psychiatry
<year>2015</year>; <volume>2</volume>:
<fpage>1002</fpage>–<lpage>1012</lpage>.<pub-id pub-id-type="pmid">26544749</pub-id></mixed-citation>
</ref>
<ref id="bibr118-2045125319858901">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>E</given-names></name><name><surname>Agrawal</surname><given-names>R</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Vulnerability imposed by diet and brain trauma
for anxiety-like phenotype: implications for post-traumatic stress
disorders</article-title>. <source/>PLoS One
<year>2013</year>; <volume>8</volume>: <fpage>e57945</fpage>.<pub-id pub-id-type="pmid">23483949</pub-id></mixed-citation>
</ref>
<ref id="bibr119-2045125319858901">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Yonemoto</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Potential role of brain-derived neurotrophic
factor in omega-3 Fatty Acid supplementation to prevent posttraumatic
distress after accidental injury: an open-label pilot study</article-title>.
<source/>Psychother Psychosom
<year>2011</year>; <volume>80</volume>:
<fpage>310</fpage>–<lpage>312</lpage>.<pub-id pub-id-type="pmid">21720194</pub-id></mixed-citation>
</ref>
<ref id="bibr120-2045125319858901">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Kalueff</surname><given-names>AV</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary eicosapentaenoic acid normalizes
hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates
glial activation and regulates BDNF function in a rodent model of
neuroinflammation induced by central interleukin-1beta
administration</article-title>. <source/>Eur J Nutr
<year>2018</year>; <volume>57</volume>:
<fpage>1781</fpage>–<lpage>1791</lpage>.<pub-id pub-id-type="pmid">28523372</pub-id></mixed-citation>
</ref>
<ref id="bibr121-2045125319858901">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okubo</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Sekiguchi</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Mechanisms underlying the effects of n-3
polyunsaturated fatty acids on fear memory processing and their hypothetical
effects on fear of cancer recurrence in cancer survivors</article-title>.
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2018</year>; <volume>131</volume>:
<fpage>14</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">29628046</pub-id></mixed-citation>
</ref>
<ref id="bibr122-2045125319858901">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsden</surname><given-names>CE</given-names></name><name><surname>Zamora</surname><given-names>D</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Diet-induced changes in n-3- and n-6-derived
endocannabinoids and reductions in headache pain and psychological
distress</article-title>. <source/>J Pain
<year>2015</year>; <volume>16</volume>:
<fpage>707</fpage>–<lpage>716</lpage>.<pub-id pub-id-type="pmid">25958314</pub-id></mixed-citation>
</ref>
<ref id="bibr123-2045125319858901">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ajith</surname><given-names>TA.</given-names></name></person-group>
<article-title>A recent update on the effects of omega-3 fatty acids in
Alzheimer’s disease</article-title>. <source/>Curr Clin Pharmacol
<year>2018</year>; <volume>13</volume>:
<fpage>252</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">30084334</pub-id></mixed-citation>
</ref>
<ref id="bibr124-2045125319858901">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burckhardt</surname><given-names>M</given-names></name><name><surname>Herke</surname><given-names>M</given-names></name><name><surname>Wustmann</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acids for the treatment of
dementia</article-title>. <source/>Cochrane Database Syst Rev
<year>2016</year>; <volume>4</volume>: CD009002.</mixed-citation>
</ref>
<ref id="bibr125-2045125319858901">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Canhada</surname><given-names>S</given-names></name><name><surname>Castro</surname><given-names>K</given-names></name><name><surname>Perry</surname><given-names>IS</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acids’ supplementation in
Alzheimer’s disease: A systematic review</article-title>. <source/>Nutr
Neurosci
<year>2018</year>; <volume>21</volume>:
<fpage>529</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">28466678</pub-id></mixed-citation>
</ref>
<ref id="bibr126-2045125319858901">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andruchow</surname><given-names>ND</given-names></name><name><surname>Konishi</surname><given-names>K</given-names></name><name><surname>Shatenstein</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>A lower ratio of omega-6 to omega-3 fatty acids
predicts better hippocampus-dependent spatial memory and cognitive status in
older adults</article-title>. <source/>Neuropsychology
<year>2017</year>; <volume>31</volume>:
<fpage>724</fpage>–<lpage>734</lpage>.<pub-id pub-id-type="pmid">28394147</pub-id></mixed-citation>
</ref>
<ref id="bibr127-2045125319858901">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hooper</surname><given-names>C</given-names></name><name><surname>De Souto Barreto</surname><given-names>P</given-names></name><name><surname>Coley</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive changes with omega-3 polyunsaturated
fatty acids in non-demented older adults with low omega-3
index</article-title>. <source/>J Nutr Health Aging
<year>2017</year>; <volume>21</volume>:
<fpage>988</fpage>–<lpage>993</lpage>.<pub-id pub-id-type="pmid">29083439</pub-id></mixed-citation>
</ref>
<ref id="bibr128-2045125319858901">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lukaschek</surname><given-names>K</given-names></name><name><surname>von Schacky</surname><given-names>C</given-names></name><name><surname>Kruse</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive Impairment Is Associated with a Low
Omega-3 Index in the Elderly: Results from the KORA-Age
Study</article-title>. <source/>Dement Geriatr Cogn Disord
<year>2016</year>; <volume>42</volume>:
<fpage>236</fpage>–<lpage>245</lpage>.<pub-id pub-id-type="pmid">27701160</pub-id></mixed-citation>
</ref>
<ref id="bibr129-2045125319858901">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Intakes of fish and polyunsaturated fatty acids
and mild-to-severe cognitive impairment risks: a dose-response meta-analysis
of 21 cohort studies</article-title>. <source/>Am J Clin Nutr
<year>2016</year>; <volume>103</volume>:
<fpage>330</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">26718417</pub-id></mixed-citation>
</ref>
<ref id="bibr130-2045125319858901">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nunes</surname><given-names>B</given-names></name><name><surname>Pinho</surname><given-names>C</given-names></name><name><surname>Sousa</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Relevance of omega-3 and omega-6/omega-3 ratio
in preventing cognitive impairment</article-title>. <source/>Acta Med
Port
<year>2017</year>; <volume>30</volume>:
<fpage>213</fpage>–<lpage>223</lpage>.<pub-id pub-id-type="pmid">28550831</pub-id></mixed-citation>
</ref>
<ref id="bibr131-2045125319858901">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pottala</surname><given-names>JV</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Robinson</surname><given-names>JG</given-names></name><etal>et al</etal></person-group>
<article-title>Higher RBC EPA + DHA corresponds with larger
total brain and hippocampal volumes: WHIMS-MRI study</article-title>.
<source/>Neurology
<year>2014</year>; <volume>82</volume>:
<fpage>435</fpage>–<lpage>442</lpage>.<pub-id pub-id-type="pmid">24453077</pub-id></mixed-citation>
</ref>
<ref id="bibr132-2045125319858901">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belkouch</surname><given-names>M</given-names></name><name><surname>Hachem</surname><given-names>M</given-names></name><name><surname>Elgot</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>The pleiotropic effects of omega-3
docosahexaenoic acid on the hallmarks of Alzheimer’s
disease</article-title>. <source/>J Nutr Biochem
<year>2016</year>; <volume>38</volume>:
<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">27825512</pub-id></mixed-citation>
</ref>
<ref id="bibr133-2045125319858901">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cansev</surname><given-names>M</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Oral administration of circulating precursors
for membrane phosphatides can promote the synthesis of new brain
synapses</article-title>. <source/>Alzheimers Dement
<year>2008</year>; <volume>4</volume>:
<fpage>S153</fpage>–<lpage>S168</lpage>.<pub-id pub-id-type="pmid">18631994</pub-id></mixed-citation>
</ref>
<ref id="bibr134-2045125319858901">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Childs</surname><given-names>CE</given-names></name><name><surname>Calder</surname><given-names>PC</given-names></name><etal>et al</etal></person-group>
<article-title>Lower omega-3 fatty acid intake and status are
associated with poorer cognitive function in older age: a comparison of
individuals with and without cognitive impairment and Alzheimer’s
disease</article-title>. <source/>Nutr Neurosci
<year>2012</year>; <volume>15</volume>:
<fpage>271</fpage>–<lpage>277</lpage>.<pub-id pub-id-type="pmid">22824373</pub-id></mixed-citation>
</ref>
<ref id="bibr135-2045125319858901">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>TL.</given-names></name></person-group>
<article-title>Omega-3 fatty acids, cognitive decline, and Alzheimer’s disease:
a critical review and evaluation of the literature</article-title>.
<source/>J Alzheimers Dis
<year>2010</year>; <volume>21</volume>:
<fpage>673</fpage>–<lpage>690</lpage>.<pub-id pub-id-type="pmid">20634589</pub-id></mixed-citation>
</ref>
<ref id="bibr136-2045125319858901">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Hossain</surname><given-names>S.</given-names></name></person-group>
<article-title>Neuroprotective and ameliorative actions of polyunsaturated fatty
acids against neuronal diseases: beneficial effect of docosahexaenoic acid
on cognitive decline in Alzheimer’s disease</article-title>. <source/>J
Pharmacol Sci
<year>2011</year>; <volume>116</volume>:
<fpage>150</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">21606627</pub-id></mixed-citation>
</ref>
<ref id="bibr137-2045125319858901">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Calon</surname><given-names>F</given-names></name><name><surname>Julien</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Docosahexaenoic acid-derived neuroprotectin D1
induces neuronal survival via secretase- and PPARgamma-mediated mechanisms
in Alzheimer’s disease models</article-title>. <source/>PLoS One
<year>2011</year>; <volume>6</volume>: <fpage>e15816</fpage>.<pub-id pub-id-type="pmid">21246057</pub-id></mixed-citation>
</ref>
<ref id="bibr138-2045125319858901">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>KN</given-names></name><name><surname>Martinez-Coria</surname><given-names>H</given-names></name><name><surname>Khashwji</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary docosahexaenoic acid and
docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a
mechanism involving presenilin 1 levels</article-title>. <source/>J
Neurosci
<year>2007</year>; <volume>27</volume>:
<fpage>4385</fpage>–<lpage>4395</lpage>.<pub-id pub-id-type="pmid">17442823</pub-id></mixed-citation>
</ref>
<ref id="bibr139-2045125319858901">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Hossain</surname><given-names>S</given-names></name><name><surname>Agdul</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Docosahexaenoic acid-induced amelioration on
impairment of memory learning in amyloid beta-infused rats relates to the
decreases of amyloid beta and cholesterol levels in detergent-insoluble
membrane fractions</article-title>. <source/>Biochim Biophys Acta
<year>2005</year>; <volume>1738</volume>:
<fpage>91</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">16427803</pub-id></mixed-citation>
</ref>
<ref id="bibr140-2045125319858901">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Calon</surname><given-names>F</given-names></name><name><surname>Morihara</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>A diet enriched with the omega-3 fatty acid
docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse
model</article-title>. <source/>J Neurosci
<year>2005</year>; <volume>25</volume>:
<fpage>3032</fpage>–<lpage>3040</lpage>.<pub-id pub-id-type="pmid">15788759</pub-id></mixed-citation>
</ref>
<ref id="bibr141-2045125319858901">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Cansev</surname><given-names>M</given-names></name><name><surname>Wurtman</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Oral supplementation with docosahexaenoic acid and
uridine-5’-monophosphate increases dendritic spine density in adult gerbil
hippocampus</article-title>. <source/>Brain Res
<year>2007</year>; <volume>1182</volume>:
<fpage>50</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">17950710</pub-id></mixed-citation>
</ref>
<ref id="bibr142-2045125319858901">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><etal>et al</etal></person-group>
<article-title>Enriched brain omega-3 polyunsaturated fatty
acids confer neuroprotection against microinfarction</article-title>.
<source/>EBioMedicine
<year>2018</year>; <volume>32</volume>:
<fpage>50</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">29880270</pub-id></mixed-citation>
</ref>
<ref id="bibr143-2045125319858901">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Fish consumption and CHD mortality: an updated
meta-analysis of seventeen cohort studies</article-title>. <source/>Public
Health Nutr
<year>2012</year>; <volume>15</volume>:
<fpage>725</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">21914258</pub-id></mixed-citation>
</ref>
<ref id="bibr144-2045125319858901">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kulzow</surname><given-names>N</given-names></name><name><surname>Witte</surname><given-names>AV</given-names></name><name><surname>Kerti</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Impact of omega-3 fatty acid supplementation on
memory functions in healthy older adults</article-title>. <source/>J
Alzheimers Dis
<year>2016</year>; <volume>51</volume>:
<fpage>713</fpage>–<lpage>725</lpage>.<pub-id pub-id-type="pmid">26890759</pub-id></mixed-citation>
</ref>
<ref id="bibr145-2045125319858901">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>CE.</given-names></name></person-group>
<article-title>Parkinson’s disease</article-title>. <source/>BMJ
<year>2007</year>; <volume>335</volume>:
<fpage>441</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">17762036</pub-id></mixed-citation>
</ref>
<ref id="bibr146-2045125319858901">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boyko</surname><given-names>AA</given-names></name><name><surname>Troyanova</surname><given-names>NI</given-names></name><name><surname>Kovalenko</surname><given-names>EI</given-names></name><etal>et al</etal></person-group>
<article-title>Similarity and differences in
inflammation-related characteristics of the peripheral immune system of
patients with Parkinson’s and Alzheimer’s diseases</article-title>.
<source/>Int J Mol Sci
<year>2017</year>; <fpage>18</fpage>.</mixed-citation>
</ref>
<ref id="bibr147-2045125319858901">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schapira</surname><given-names>AH.</given-names></name></person-group>
<article-title>Mitochondria in the aetiology and pathogenesis of Parkinson’s
disease</article-title>. <source/>Parkinsonism Relat Disord
<year>1999</year>; <volume>5</volume>:
<fpage>139</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">18591132</pub-id></mixed-citation>
</ref>
<ref id="bibr148-2045125319858901">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dias</surname><given-names>V</given-names></name><name><surname>Junn</surname><given-names>E</given-names></name><name><surname>Mouradian</surname><given-names>MM.</given-names></name></person-group>
<article-title>The role of oxidative stress in Parkinson’s
disease</article-title>. <source/>J Parkinsons Dis
<year>2013</year>; <volume>3</volume>:
<fpage>461</fpage>–<lpage>491</lpage>.<pub-id pub-id-type="pmid">24252804</pub-id></mixed-citation>
</ref>
<ref id="bibr149-2045125319858901">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Connolly</surname><given-names>BS</given-names></name><name><surname>Lang</surname><given-names>AE.</given-names></name></person-group>
<article-title>Pharmacological treatment of Parkinson disease: a
review</article-title>. <source/>JAMA
<year>2014</year>; <volume>311</volume>:
<fpage>1670</fpage>–<lpage>1683</lpage>.<pub-id pub-id-type="pmid">24756517</pub-id></mixed-citation>
</ref>
<ref id="bibr150-2045125319858901">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalinderi</surname><given-names>K</given-names></name><name><surname>Papaliagkas</surname><given-names>V</given-names></name><name><surname>Fidani</surname><given-names>L</given-names></name></person-group>
<article-title>Pharmacogenetics and levodopa induced motor
complications</article-title>. <source/>Int J Neurosci
<volume>2018</volume>: <fpage>1</fpage>–<lpage>31</lpage>.</mixed-citation>
</ref>
<ref id="bibr151-2045125319858901">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fung</surname><given-names>TT</given-names></name><etal>et al</etal></person-group>
<article-title>Prospective study of dietary pattern and risk of
Parkinson disease</article-title>. <source/>Am J Clin Nutr
<year>2007</year>; <volume>86</volume>:
<fpage>1486</fpage>–<lpage>1494</lpage>.<pub-id pub-id-type="pmid">17991663</pub-id></mixed-citation>
</ref>
<ref id="bibr152-2045125319858901">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okubo</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary patterns and risk of Parkinson’s
disease: a case-control study in Japan</article-title>. <source/>Eur J
Neurol
<year>2012</year>; <volume>19</volume>:
<fpage>681</fpage>–<lpage>688</lpage>.<pub-id pub-id-type="pmid">22136555</pub-id></mixed-citation>
</ref>
<ref id="bibr153-2045125319858901">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Lau</surname><given-names>LM</given-names></name><name><surname>Bornebroek</surname><given-names>M</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary fatty acids and the risk of Parkinson
disease: the Rotterdam study</article-title>. <source/>Neurology
<year>2005</year>; <volume>64</volume>:
<fpage>2040</fpage>–<lpage>2045</lpage>.<pub-id pub-id-type="pmid">15985568</pub-id></mixed-citation>
</ref>
<ref id="bibr154-2045125319858901">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taghizadeh</surname><given-names>M</given-names></name><name><surname>Tamtaji</surname><given-names>OR</given-names></name><name><surname>Dadgostar</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>The effects of omega-3 fatty acids and vitamin E
co-supplementation on clinical and metabolic status in patients with
Parkinson’s disease: a randomized, double-blind, placebo-controlled
trial</article-title>. <source/>Neurochem Int
<year>2017</year>; <volume>108</volume>:
<fpage>183</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">28342967</pub-id></mixed-citation>
</ref>
<ref id="bibr155-2045125319858901">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyake</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Dietary fat intake and risk of Parkinson’s
disease: a case-control study in Japan</article-title>. <source/>J Neurol
Sci
<year>2010</year>; <volume>288</volume>:
<fpage>117</fpage>–<lpage>122</lpage>.<pub-id pub-id-type="pmid">19819467</pub-id></mixed-citation>
</ref>
<ref id="bibr156-2045125319858901">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orr</surname><given-names>SK</given-names></name><name><surname>Trepanier</surname><given-names>MO</given-names></name><name><surname>Bazinet</surname><given-names>RP.</given-names></name></person-group>
<article-title>n-3 Polyunsaturated fatty acids in animal models with
neuroinflammation</article-title>. <source/>Prostaglandins Leukot Essent
Fatty Acids
<year>2013</year>; <volume>88</volume>:
<fpage>97</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">22770766</pub-id></mixed-citation>
</ref>
<ref id="bibr157-2045125319858901">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>HD</given-names></name><name><surname>dos Santos Junior</surname><given-names>EF</given-names></name><name><surname>de Santana</surname><given-names>DF</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 deficiency and neurodegeneration in the
substantia nigra: involvement of increased nitric oxide production and
reduced BDNF expression</article-title>. <source/>Biochim Biophys
Acta
<year>2014</year>; <volume>1840</volume>:
<fpage>1902</fpage>–<lpage>1912</lpage>.<pub-id pub-id-type="pmid">24361617</pub-id></mixed-citation>
</ref>
<ref id="bibr158-2045125319858901">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>MA</given-names></name><name><surname>Delattre</surname><given-names>AM</given-names></name><name><surname>Carabelli</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Neuroprotective effect of omega-3
polyunsaturated fatty acids in the 6-OHDA model of Parkinson’s disease is
mediated by a reduction of inducible nitric oxide synthase</article-title>.
<source/>Nutr Neurosci
<year>2018</year>; <volume>21</volume>:
<fpage>341</fpage>–<lpage>351</lpage>.<pub-id pub-id-type="pmid">28221817</pub-id></mixed-citation>
</ref>
<ref id="bibr159-2045125319858901">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeGiorgio</surname><given-names>CM</given-names></name><name><surname>Miller</surname><given-names>PR</given-names></name><name><surname>Harper</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Fish oil (n-3 fatty acids) in drug resistant
epilepsy: a randomised placebo-controlled crossover study</article-title>.
<source/>J Neurol Neurosurg Psychiatry
<year>2015</year>; <volume>86</volume>:
<fpage>65</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">25201887</pub-id></mixed-citation>
</ref>
<ref id="bibr160-2045125319858901">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>FAS</given-names></name><name><surname>Ghebremeskel</surname><given-names>K</given-names></name><name><surname>Abdel-Rahman</surname><given-names>ME</given-names></name><etal>et al</etal></person-group>
<article-title>The differential effects of eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) on seizure frequency in patients
with drug-resistant epilepsy - A randomized, double-blind,
placebo-controlled trial</article-title>. <source/>Epilepsy Behav
<year>2018</year>; <volume>87</volume>:
<fpage>32</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">30170260</pub-id></mixed-citation>
</ref>
<ref id="bibr161-2045125319858901">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Omrani</surname><given-names>S</given-names></name><name><surname>Taheri</surname><given-names>M</given-names></name><name><surname>Omrani</surname><given-names>MD</given-names></name><etal>et al</etal></person-group>
<article-title>The effect of omega-3 fatty acids on clinical
and paraclinical features of intractable epileptic patients: a triple blind
randomized clinical trial</article-title>. <source/>Clin Transl Med
<year>2019</year>; <volume>8</volume>: <fpage>3</fpage>.<pub-id pub-id-type="pmid">30649643</pub-id></mixed-citation>
</ref>
<ref id="bibr162-2045125319858901">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuen</surname><given-names>AW</given-names></name><name><surname>Flugel</surname><given-names>D</given-names></name><name><surname>Poepel</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Non-randomized open trial of eicosapentaenoic
acid (EPA), an omega-3 fatty acid, in ten people with chronic
epilepsy</article-title>. <source/>Epilepsy Behav
<year>2012</year>; <volume>23</volume>:
<fpage>370</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">22342198</pub-id></mixed-citation>
</ref>
<ref id="bibr163-2045125319858901">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kouchaki</surname><given-names>E</given-names></name><name><surname>Afarini</surname><given-names>M</given-names></name><name><surname>Abolhassani</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>High-dose omega-3 fatty acid plus vitamin D3
supplementation affects clinical symptoms and metabolic status of patients
with multiple sclerosis: a randomized controlled clinical
trial</article-title>. <source/>J Nutr
<year>2018</year>; <volume>148</volume>:
<fpage>1380</fpage>–<lpage>1386</lpage>.<pub-id pub-id-type="pmid">29982544</pub-id></mixed-citation>
</ref>
<ref id="bibr164-2045125319858901">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marck</surname><given-names>CH</given-names></name><name><surname>De Livera</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><etal>et al</etal></person-group>
<article-title>Health outcomes and adherence to a healthy
lifestyle after a multimodal intervention in people with multiple sclerosis:
three year follow-up</article-title>. <source/>PLoS One
<year>2018</year>; <volume>13</volume>:
<fpage>e0197759</fpage>.<pub-id pub-id-type="pmid">29791509</pub-id></mixed-citation>
</ref>
<ref id="bibr165-2045125319858901">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mousavi Nasl-Khameneh</surname><given-names>A</given-names></name><name><surname>Mirshafiey</surname><given-names>A</given-names></name><name><surname>Naser Moghadasi</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Combination treatment of docosahexaenoic acid
(DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORgammat gene
expression in PBMCs of patients with relapsing-remitting multiple
sclerosis</article-title>. <source/>Neurol Res
<year>2018</year>; <volume>40</volume>:
<fpage>11</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">29155646</pub-id></mixed-citation>
</ref>
<ref id="bibr166-2045125319858901">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pantzaris</surname><given-names>MC</given-names></name><name><surname>Loukaides</surname><given-names>GN</given-names></name><name><surname>Ntzani</surname><given-names>EE</given-names></name><etal>et al</etal></person-group>
<article-title>A novel oral nutraceutical formula of omega-3
and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting
multiple sclerosis: a randomised, double-blind, placebo-controlled
proof-of-concept clinical trial</article-title>. <source/>BMJ Open
<year>2013</year>; <fpage>3</fpage></mixed-citation>
</ref>
<ref id="bibr167-2045125319858901">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riccio</surname><given-names>P</given-names></name><name><surname>Rossano</surname><given-names>R</given-names></name><name><surname>Larocca</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Anti-inflammatory nutritional intervention in
patients with relapsing-remitting and primary-progressive multiple
sclerosis: a pilot study</article-title>. <source/>Exp Biol Med
(Maywood)
<year>2016</year>; <volume>241</volume>:
<fpage>620</fpage>–<lpage>635</lpage>.<pub-id pub-id-type="pmid">26785711</pub-id></mixed-citation>
</ref>
<ref id="bibr168-2045125319858901">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnold</surname><given-names>LE</given-names></name><name><surname>Young</surname><given-names>AS</given-names></name><name><surname>Belury</surname><given-names>MA</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acid plasma levels before and
after supplementation: correlations with mood and clinical outcomes in the
omega-3 and therapy studies</article-title>. <source/>J Child Adolesc
Psychopharmacol
<year>2017</year>; <volume>27</volume>:
<fpage>223</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">28157380</pub-id></mixed-citation>
</ref>
<ref id="bibr169-2045125319858901">
<label>169</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fristad</surname><given-names>MA</given-names></name><name><surname>Young</surname><given-names>AS</given-names></name><name><surname>Vesco</surname><given-names>AT</given-names></name><etal>et al</etal></person-group>
<article-title>A randomized controlled trial of individual
family psychoeducational psychotherapy and omega-3 fatty acids in youth with
subsyndromal bipolar disorder</article-title>. <source/>J Child Adolesc
Psychopharmacol
<year>2015</year>; <volume>25</volume>:
<fpage>764</fpage>–<lpage>774</lpage>.<pub-id pub-id-type="pmid">26682997</pub-id></mixed-citation>
</ref>
<ref id="bibr170-2045125319858901">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>J</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>A randomized clinical trial of high
eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in
combination in the treatment of pediatric bipolar spectrum disorders: a
pilot study</article-title>. <source/>J Clin Psychiatry
<year>2015</year>; <volume>76</volume>:
<fpage>1548</fpage>–<lpage>1555</lpage>.<pub-id pub-id-type="pmid">26646031</pub-id></mixed-citation>
</ref>
<ref id="bibr171-2045125319858901">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayton</surname><given-names>AK</given-names></name><name><surname>Azaz</surname><given-names>A</given-names></name><name><surname>Horrobin</surname><given-names>DF.</given-names></name></person-group>
<article-title>A pilot open case series of ethyl-EPA supplementation in the
treatment of anorexia nervosa</article-title>. <source/>Prostaglandins Leukot
Essent Fatty Acids
<year>2004</year>; <volume>71</volume>:
<fpage>205</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="pmid">15301789</pub-id></mixed-citation>
</ref>
<ref id="bibr172-2045125319858901">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbarich</surname><given-names>NC</given-names></name><name><surname>McConaha</surname><given-names>CW</given-names></name><name><surname>Halmi</surname><given-names>KA</given-names></name><etal>et al</etal></person-group>
<article-title>Use of nutritional supplements to increase the
efficacy of fluoxetine in the treatment of anorexia nervosa</article-title>.
<source/>Int J Eat Disord
<year>2004</year>; <volume>35</volume>:
<fpage>10</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">14705152</pub-id></mixed-citation>
</ref>
<ref id="bibr173-2045125319858901">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manos</surname><given-names>BE</given-names></name><name><surname>Bravender</surname><given-names>TD</given-names></name><name><surname>Harrison</surname><given-names>TM</given-names></name><etal>et al</etal></person-group>
<article-title>A pilot randomized controlled trial of omega-3
fatty acid supplementation for the treatment of anxiety in adolescents with
anorexia nervosa</article-title>. <source/>Int J Eat Disord
<year>2018</year>; <volume>51</volume>:
<fpage>1367</fpage>–<lpage>1372</lpage>.<pub-id pub-id-type="pmid">30367519</pub-id></mixed-citation>
</ref>
<ref id="bibr174-2045125319858901">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozzatello</surname><given-names>P</given-names></name><name><surname>Rocca</surname><given-names>P</given-names></name><name><surname>Bellino</surname><given-names>S.</given-names></name></person-group>
<article-title>Combination of omega-3 fatty acids and valproic acid in treatment
of borderline personality disorder: a follow-up study</article-title>.
<source/>Clin Drug Investig
<year>2018</year>; <volume>38</volume>:
<fpage>367</fpage>–<lpage>372</lpage>.</mixed-citation>
</ref>
<ref id="bibr175-2045125319858901">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amminger</surname><given-names>GP</given-names></name><name><surname>Chanen</surname><given-names>AM</given-names></name><name><surname>Ohmann</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acid supplementation in
adolescents with borderline personality disorder and ultra-high risk
criteria for psychosis: a post hoc subgroup analysis of a double-blind,
randomized controlled trial</article-title>. <source/>Can J
Psychiatry
<year>2013</year>; <volume>58</volume>:
<fpage>402</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">23870722</pub-id></mixed-citation>
</ref>
<ref id="bibr176-2045125319858901">
<label>176</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanarini</surname><given-names>MC</given-names></name><name><surname>Frankenburg</surname><given-names>FR.</given-names></name></person-group>
<article-title>omega-3 Fatty acid treatment of women with borderline personality
disorder: a double-blind, placebo-controlled pilot study</article-title>.
<source/>Am J Psychiatry
<year>2003</year>; <volume>160</volume>:
<fpage>167</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">12505817</pub-id></mixed-citation>
</ref>
<ref id="bibr177-2045125319858901">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amminger</surname><given-names>GP</given-names></name><name><surname>Berger</surname><given-names>GE</given-names></name><name><surname>Schafer</surname><given-names>MR</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-3 fatty acids supplementation in children
with autism: a double-blind randomized, placebo-controlled pilot
study</article-title>. <source/>Biol Psychiatry
<year>2007</year>; <volume>61</volume>:
<fpage>551</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">16920077</pub-id></mixed-citation>
</ref>
<ref id="bibr178-2045125319858901">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazahery</surname><given-names>H</given-names></name><name><surname>Conlon</surname><given-names>CA</given-names></name><name><surname>Beck</surname><given-names>KL</given-names></name><etal>et al</etal></person-group>
<article-title>A randomised controlled trial of vitamin D and
omega-3 long chain polyunsaturated fatty acids in the treatment of
irritability and hyperactivity among children with autism spectrum
disorder</article-title>. <source/>J Steroid Biochem Mol Biol
<year>2019</year>; <volume>187</volume>:
<fpage>9</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">30744880</pub-id></mixed-citation>
</ref>
<ref id="bibr179-2045125319858901">
<label>179</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazahery</surname><given-names>H</given-names></name><name><surname>Conlon</surname><given-names>CA</given-names></name><name><surname>Beck</surname><given-names>KL</given-names></name><etal>et al</etal></person-group>
<article-title>A randomised-controlled trial of vitamin d and
omega-3 long chain polyunsaturated fatty acids in the treatment of core
symptoms of autism spectrum disorder in children</article-title>. <source/>J
Autism Dev Disord
<year>2019</year>; <volume>49</volume>:
<fpage>1778</fpage>–<lpage>1794</lpage>.<pub-id pub-id-type="pmid">30607782</pub-id></mixed-citation>
</ref>
<ref id="bibr180-2045125319858901">
<label>180</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keim</surname><given-names>SA</given-names></name><name><surname>Gracious</surname><given-names>B</given-names></name><name><surname>Boone</surname><given-names>KM</given-names></name><etal>et al</etal></person-group>
<article-title>omega-3 and omega-6 fatty acid supplementation
may reduce autism symptoms based on parent report in preterm
toddlers</article-title>. <source/>J Nutr
<year>2018</year>; <volume>148</volume>:
<fpage>227</fpage>–<lpage>235</lpage>.<pub-id pub-id-type="pmid">29490101</pub-id></mixed-citation>
</ref>
<ref id="bibr181-2045125319858901">
<label>181</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>YS</given-names></name><name><surname>Tseng</surname><given-names>PT</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><etal>et al</etal></person-group>
<article-title>Supplementation of omega 3 fatty acids may
improve hyperactivity, lethargy, and stereotypy in children with autism
spectrum disorders: a meta-analysis of randomized controlled
trials</article-title>. <source/>Neuropsychiatr Dis Treat
<year>2017</year>; <volume>13</volume>:
<fpage>2531</fpage>–<lpage>2543</lpage>.<pub-id pub-id-type="pmid">29042783</pub-id></mixed-citation>
</ref>
<ref id="bibr182-2045125319858901">
<label>182</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caspar-Bauguil</surname><given-names>S</given-names></name><name><surname>Montastier</surname><given-names>E</given-names></name><name><surname>Galinon</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Anorexia nervosa patients display a deficit in
membrane long chain poly-unsaturated fatty acids</article-title>.
<source/>Clin Nutr
<year>2012</year>; <volume>31</volume>:
<fpage>386</fpage>–<lpage>390</lpage>.<pub-id pub-id-type="pmid">22385730</pub-id></mixed-citation>
</ref>
<ref id="bibr183-2045125319858901">
<label>183</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bahagat</surname><given-names>KA</given-names></name><name><surname>Elhady</surname><given-names>M</given-names></name><name><surname>Aziz</surname><given-names>AA</given-names></name><etal>et al</etal></person-group>
<article-title>Omega-6/omega-3 ratio and cognition in children
with epilepsy</article-title>. <source/>An Pediatr (Barc)
<year>2019</year>. pii: S1695-4033(18)30544-7.</mixed-citation>
</ref>
<ref id="bibr184-2045125319858901">
<label>184</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuen</surname><given-names>AW</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name><name><surname>Flugel</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Erythrocyte and plasma fatty acid profiles in
patients with epilepsy: does carbamazepine affect omega-3 fatty acid
concentrations?</article-title>
<source/>Epilepsy Behav
<year>2008</year>; <volume>12</volume>:
<fpage>317</fpage>–<lpage>323</lpage>.<pub-id pub-id-type="pmid">18068523</pub-id></mixed-citation>
</ref>
<ref id="bibr185-2045125319858901">
<label>185</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjornevik</surname><given-names>K</given-names></name><name><surname>Chitnis</surname><given-names>T</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Polyunsaturated fatty acids and the risk of
multiple sclerosis</article-title>. <source/>Mult Scler
<year>2017</year>; <volume>23</volume>:
<fpage>1830</fpage>–<lpage>1838</lpage>.<pub-id pub-id-type="pmid">28156186</pub-id></mixed-citation>
</ref>
<ref id="bibr186-2045125319858901">
<label>186</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wulsin</surname><given-names>LR</given-names></name><name><surname>Blom</surname><given-names>TJ</given-names></name><name><surname>Durling</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Cardiometabolic risks and omega-3 index in
recent-onset bipolar I disorder</article-title>. <source/>Bipolar
Disord
<year>2018</year>; <volume>20</volume>:
<fpage>658</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">29479787</pub-id></mixed-citation>
</ref>
<ref id="bibr187-2045125319858901">
<label>187</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McNamara</surname><given-names>RK</given-names></name><name><surname>Welge</surname><given-names>JA.</given-names></name></person-group>
<article-title>Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus
in bipolar disorder</article-title>. <source/>Bipolar Disord
<year>2016</year>; <volume>18</volume>:
<fpage>300</fpage>–<lpage>306</lpage>.<pub-id pub-id-type="pmid">27087497</pub-id></mixed-citation>
</ref>
<ref id="bibr188-2045125319858901">
<label>188</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saunders</surname><given-names>EF</given-names></name><name><surname>Reider</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Low unesterified:esterified eicosapentaenoic
acid (EPA) plasma concentration ratio is associated with bipolar disorder
episodes, and omega-3 plasma concentrations are altered by
treatment</article-title>. <source/>Bipolar Disord
<year>2015</year>; <volume>17</volume>:
<fpage>729</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">26424416</pub-id></mixed-citation>
</ref>
<ref id="bibr189-2045125319858901">
<label>189</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteban-Figuerola</surname><given-names>P</given-names></name><name><surname>Canals</surname><given-names>J</given-names></name><name><surname>Fernandez-Cao</surname><given-names>JC</given-names></name><etal>et al</etal></person-group>
<article-title>Differences in food consumption and nutritional
intake between children with autism spectrum disorders and typically
developing children: A meta-analysis</article-title>.
<source/>Autism
<volume>2018</volume>: <fpage>1362361318794179</fpage>.</mixed-citation>
</ref>
<ref id="bibr190-2045125319858901">
<label>190</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brasky</surname><given-names>TM</given-names></name><name><surname>Darke</surname><given-names>AK</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><etal>et al</etal></person-group>
<article-title>Plasma phospholipid fatty acids and prostate
cancer risk in the SELECT trial</article-title>. <source/>J Natl Cancer
Inst
<year>2013</year>; <volume>105</volume>:
<fpage>1132</fpage>–<lpage>1141</lpage>.<pub-id pub-id-type="pmid">23843441</pub-id></mixed-citation>
</ref>
<ref id="bibr191-2045125319858901">
<label>191</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brenna</surname><given-names>JT</given-names></name><name><surname>Burdge</surname><given-names>GC</given-names></name><name><surname>Crawford</surname><given-names>MA</given-names></name><etal>et al</etal></person-group>
<article-title>RE: Plasma phospholipid fatty acids and prostate
cancer risk in the SELECT trial</article-title>. <source/>J Natl Cancer
Inst
<year>2014</year>; <volume>106</volume>: dju015.</mixed-citation>
</ref>
<ref id="bibr192-2045125319858901">
<label>192</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Davidson</surname><given-names>MH.</given-names></name></person-group>
<article-title>RE: Plasma phospholipid fatty acids and prostate cancer risk in
the SELECT trial</article-title>. <source/>J Natl Cancer Inst
<year>2014</year>; <volume>106</volume>: dju019.</mixed-citation>
</ref>
<ref id="bibr193-2045125319858901">
<label>193</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCarty</surname><given-names>MF</given-names></name><name><surname>Dinicolantonio</surname><given-names>JJ</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group>
<article-title>RE: Plasma phospholipid fatty acids and prostate
cancer risk in the SELECT trial</article-title>. <source/>J Natl Cancer
Inst
<year>2014</year>; <volume>106</volume>: dju014.</mixed-citation>
</ref>
<ref id="bibr194-2045125319858901">
<label>194</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Backes</surname><given-names>J</given-names></name><name><surname>Anzalone</surname><given-names>D</given-names></name><name><surname>Hilleman</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>The clinical relevance of omega-3 fatty acids in
the management of hypertriglyceridemia</article-title>. <source/>Lipids
Health Dis
<year>2016</year>; <volume>15</volume>: <fpage>118</fpage>.<pub-id pub-id-type="pmid">27444154</pub-id></mixed-citation>
</ref>
<ref id="bibr195-2045125319858901">
<label>195</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>S.</given-names></name></person-group>
<article-title>Effects of omega-3 fatty acid supplementation on glucose control
and lipid levels in type 2 diabetes: a meta-analysis</article-title>.
<source/>PLoS One
<year>2015</year>; <volume>10</volume>:
<fpage>e0139565</fpage>.<pub-id pub-id-type="pmid">26431431</pub-id></mixed-citation>
</ref>
<ref id="bibr196-2045125319858901">
<label>196</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeansen</surname><given-names>S</given-names></name><name><surname>Witkamp</surname><given-names>RF</given-names></name><name><surname>Garthoff</surname><given-names>JA</given-names></name><etal>et al</etal></person-group>
<article-title>Fish oil LC-PUFAs do not affect blood
coagulation parameters and bleeding manifestations: analysis of 8 clinical
studies with selected patient groups on omega-3-enriched medical
nutrition</article-title>. <source/>Clin Nutr
<year>2018</year>; <volume>37</volume>:
<fpage>948</fpage>–<lpage>957</lpage>.<pub-id pub-id-type="pmid">28427779</pub-id></mixed-citation>
</ref>
<ref id="bibr197-2045125319858901">
<label>197</label>
<mixed-citation publication-type="journal">
<collab>FDA</collab>. <article-title>Substances affirmed as generally recognized
as safe: menhaden oil</article-title>. <source/>Federal Register
<year>2004</year>; <volume>69</volume>: <year>2313</year>.</mixed-citation>
</ref>
<ref id="bibr198-2045125319858901">
<label>198</label>
<mixed-citation publication-type="journal">
<collab>EFSA Panel on Dietetic Products Nutrition and Allergies (NDA)</collab>.
<article-title>Scientific Opinion related to the Tolerable Upper Intake
Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and
docosapentaenoic acid (DPA)</article-title>. <source/>EFSA Journal
<year>2012</year>; <volume>10</volume>: <year>2815</year>.</mixed-citation>
</ref>
<ref id="bibr199-2045125319858901">
<label>199</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlier</surname><given-names>H</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Caselli</surname><given-names>C.</given-names></name></person-group>
<article-title>Digestion and absorption of polyunsaturated fatty
acids</article-title>. <source/>Reprod Nutr Dev
<year>1991</year>; <volume>31</volume>:
<fpage>475</fpage>–<lpage>500</lpage>.<pub-id pub-id-type="pmid">1768307</pub-id></mixed-citation>
</ref>
<ref id="bibr200-2045125319858901">
<label>200</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dyerberg</surname><given-names>J</given-names></name><name><surname>Madsen</surname><given-names>P</given-names></name><name><surname>Moller</surname><given-names>JM</given-names></name><etal>et al</etal></person-group>
<article-title>Bioavailability of marine n-3 fatty acid
formulations</article-title>. <source/>Prostaglandins Leukot Essent Fatty
Acids
<year>2010</year>; <volume>83</volume>:
<fpage>137</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">20638827</pub-id></mixed-citation>
</ref>
<ref id="bibr201-2045125319858901">
<label>201</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lawson</surname><given-names>LD</given-names></name><name><surname>Hughes</surname><given-names>BG.</given-names></name></person-group>
<article-title>Human absorption of fish oil fatty acids as triacylglycerols,
free acids, or ethyl esters</article-title>. <source/>Biochem Biophys Res
Commun
<year>1988</year>; <volume>152</volume>:
<fpage>328</fpage>–<lpage>335</lpage>.<pub-id pub-id-type="pmid">3358766</pub-id></mixed-citation>
</ref>
<ref id="bibr202-2045125319858901">
<label>202</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neubronner</surname><given-names>J</given-names></name><name><surname>Schuchardt</surname><given-names>JP</given-names></name><name><surname>Kressel</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Enhanced increase of omega-3 index in response
to long-term n-3 fatty acid supplementation from triacylglycerides versus
ethyl esters</article-title>. <source/>Eur J Clin Nutr
<year>2011</year>; <volume>65</volume>:
<fpage>247</fpage>–<lpage>254</lpage>.<pub-id pub-id-type="pmid">21063431</pub-id></mixed-citation>
</ref>
<ref id="bibr203-2045125319858901">
<label>203</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>DD</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kushiro</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Divergent effects of eicosapentaenoic and
docosahexaenoic acid ethyl esters, and fish oil on hepatic fatty acid
oxidation in the rat</article-title>. <source/>Biochim Biophys Acta
<year>2003</year>; <volume>1635</volume>:
<fpage>29</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">14642774</pub-id></mixed-citation>
</ref>
<ref id="bibr204-2045125319858901">
<label>204</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><etal>et al</etal></person-group>
<article-title>Marine n-3 fatty acids and prevention of
cardiovascular disease and cancer</article-title>. <source/>N Engl J
Med
<year>2019</year>; <volume>380</volume>:
<fpage>23</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">30415637</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>